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Abstract
Parkinson´s Disease (PD) is a neurodegenerative movement disorder resulting from 
loss of dopaminergic (DA) neurons in substantia nigra (SN). Possible causative treat-
ment strategies for PD include neurotrophic factors, which protect and in some cases 
restore the function of dopaminergic neurons. Glial cell line-derived neurotrophic factor 
(GDNF) family of neurotrophic factors have been to date the most promising candidates 
for treatment of PD, demonstrating both neuroprotective and neurorestorative proper-
ties.
We have investigated the role of GDNF in the rodent dopaminergic system and its 
possible crosstalk with other growth factors. We characterized the GDNF-induced gene 
expression changes by DNA microarray analysis in diff erent neuronal systems, including 
in vitro cultured Neuro2A cells treated with GDNF, as well as midbrains from GDNF 
heterozygous (Hz) knockout mice. Th ese microarray experiments, resulted in the iden-
tifi cation of GDNF-induced genes, which were also confi rmed by other methods. Fur-
ther analysis of the dopaminergic system of GDNF Hz mice demonstrated about 40% 
reduction in GDNF levels, revealed increased intracellular dopamine concentrations and 
FosB/DeltaFosB expression in striatal areas. Th ese animals did not show any signifi cant 
changes in behavioural analysis of acute and repeated cocaine administration on loco-
motor activity, nor did they exhibit any changes in dopamine output following treatment 
with acute cocaine. 
We further analysed the signifi cance of GDNF receptor RET signalling in the dopa-
minergic system of MEN2B knock-in animals with constitutively active Ret. Th e MEN2B 
animals showed a robust increase in extracellular dopamine and its metabolite levels in 
striatum, increased tyrosine hydroxylase (TH) and dopamine transporter (DAT) protein 
levels by immunohistochemical staining and Western blotting, as well as increased Th  
mRNA levels in SN. MEN2B mice had increased number of DA neurons in SN by about 
25% and they also exhibited increased sensitivity to the stimulatory eff ects of cocaine. 
We also developed a semi-throughput in vitro micro-island assay for the quantifi ca-
tion of neuronal survival and TH levels by computer-assisted methodology from limited 
amounts of tissue. Th is assay can be applied for the initial screening for dopaminotrophic 
molecules, as well as for chemical drug library screening. It is applicable to any neuronal 
system for the screening of neurotrophic molecules.  
Since our microarray experiments revealed possible GDNF-VEGF-C crosstalk we 
further concentrated on studying the neurotrophic eff ects of VEGF-C. We showed that 
VEGF-C acts as a neurotrophic molecule for the DA neurons both in vitro and in vivo, 
however without additive eff ect when used together with GDNF.  Th e neuroprotective 
eff ect for VEGF-C in vivo in rat 6-OHDA model of PD was demonstrated. Th e possible 
signalling mechanisms of VEGF-C in the nervous system were investigated - infusion 
of VEGF-C to rat brain induced ERK activation, however no direct activation of RET 
signalling in vitro was found. VEGF-C treatment of rat striatum lead to up-regulation of 
VEGFR-1-3, indicating that VEGF-C can regulate the expression level of its own recep-
tor. VEGF-C dopaminotrophic activity in vivo was further supported by increased vas-
cular tissue in the neuroprotection experiments. 

11. REVIEW OF THE LITERATURE
the internal capsule white matter and con-
nected by ventrally lying fundus. These 
structures form the nigrostriatal dopa-
minergic system. The dorsal striatum 
receives aff erent inputs from the cortex, 
from the substantia nigra and sends eff er-
ent input to both external and internal 
globus pallidus, SNpc and pars reticulata 
of SN (SNpr) via GABAergic neurons. 
Only 3-5 % of the total neurons in the 
SN are dopaminergic neurons. Although 
their numbers are low, these neurons are 
strongly associated with motor function 
and voluntary movement (Kandel 2000; 
Chinta and Andersen 2005). 
Medial to the nigrostrital system 
lay the mesolimbical and mesocortical 
dopaminergic systems, which arise from 
1.1 Brain dopaminergic system 
Dopamine is one of the main monoami-
nergic neurotransmitters in the central 
nervous system. The mesodiencephalic 
dopaminergic (mDA) neurons – respon-
sible for the major source of dopamine in 
the brain - reside in the ventral mesodi-
encephalon. mDA neurons can be further 
divided into anatomically and function-
ally diff erent subgroups (Fig.1). 
Th e majority of dopaminergic neu-
ron cell bodies reside in the ventral mid-
brain consisting of substantia nigra pars 
compacta (SNpc, A9 region) with axons 
projecting to the dorsal striatum: con-
sisting of caudate nucleus (medially) and 
putamen (laterally) which are divided by 
Figure 1. Schematic presentation of human midbrain dopaminergic system. Author: Maarja 
Kotkas, modifi ed by Anu Planken.
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2the ventral tegmental area (VTA, A10) 
and project to nucleus accumbens/ olfac-
tory bulb (also referred to as the ventral 
striatum) and cortex, respectively. Th ese 
systems are thought to be responsible 
for behavioural processes such as mood, 
motivation, reward, addiction and stress 
(Kandel 2000; Chinta and Andersen 
2005). 
Dopaminergic neurons have also 
signifi cant functions outside the nervous 
system, having central roles in cardiovas-
cular, renal, enteric and hormonal func-
tioning in both humans and rodents. 
1.1.1 Development of the midbrain 
dopaminergic system 
Dopaminergic cell development is com-
plex and involves a series of processes 
and molecules. It can be further divided 
into early developmental events, such as 
regional specification, neuronal specifi-
cation and differentiation. These initial 
events are influenced by both extrinsic 
and intrinsic signals. Extrinsic signals 
from fi broblast growth factor-8 (FGF-8), 
sonic hedgehog (Shh) and transform-
ing growth factor-β2 and β3, along with 
Wnt1 and Wnt5a induce the action of 
internal transcription factors like Nurr 1, 
engrailed -1 and -2, Pitx3, and members 
of the LIM homeobox family (Lmx1a and 
Lmx1b). The result is the generation of 
post-mitotic young neurons from mitotic 
cells, with fate of becoming fully diff eren-
tiated mesencephalic dopamine neurons 
(Smits, Burbach et al. 2006; Smidt and 
Burbach 2007; Andressoo and Saarma 
2008). 
Later developmental events include 
the migration and path-fi nding of young 
mDA neurons, neurite outgrowth, guid-
ance, pruning, synapse formation, con-
nectivity and maintenance of the dopa-
minergic system. Th ese events  involve a 
wide variety of molecular clues, central 
players being ephrins, netrins, semapho-
rins, plexins, neuropilins and Slits and 
their cognate receptors (Smits, Burbach 
et al. 2006; Smidt and Burbach 2007; 
Andressoo and Saarma 2008). In addition, 
other molecules necessary for formation 
and maintenance of mDA tracts include: 
the neurotrophic factors – GDNF, neur-
turin (NRTN), mesencephalic astrocyte-
derived neurotrophic factor (MANF), 
cerebral dopamine neurotrophic fac-
tor (CDNF); morphogens –Wnt-1 and 
-8, bone morphogenetic protein 4 and 7 
(BMP-4, -7), Shh; transcription factors 
– engrailed-1/2; proteoglycans; leucine 
rich-repeat proteins and neurotransmit-
ters (Smits, Burbach et al. 2006; Smidt 
and Burbach 2007; Andressoo and Saar-
ma 2008; Van den Heuvel and Pasterkamp 
2008). 
Th e classic principle of neural devel-
opment states that neurons are created 
in excess during embryogenesis, they 
compete for limited amounts of neuro-
trophic factors and the neurons which fail 
to receive neurotrophic support undergo 
embryonic or postnatal cell death. The 
developmental cell death of midbrain DA 
neurons is considered to be biphasic - the 
first phase of apoptosis in rats starts at 
embryonic day 20 (E20) and ends by post-
natal day (P) 8-12 and the second peak is 
initiated at P14 and ceased by P28 (Burke 
2004). Knowledge about the molecular 
mechanism of these two phases is limited, 
although the first phase is likely due to 
the limited supply of factors in the stria-
tal target tissue, however no clear expla-
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3nation for the second phase exists (Burke 
2004). Although there is some evidence 
that GDNF may be involved in the regula-
tion of the number of nigral DA neurons, 
further studies on conditional knockout 
(cKO) animals are needed to clarify this 
point.  In addition other factors, such 
as NRTN, CDNF and MANF may play 
important roles here.
1.2 Parkinson’s disease
1.2.1 E? opathogenesis of  
Parkinson’s disease
Parkinson’s disease - characterized by pro-
gressive degeneration of the dopaminer-
gic system - aff ects approximately 1% of 
the population over 60 years of age and 
about 5% of the population over 85. PD 
is primarily sporadic, however rare famil-
ial genetic forms exist in about 10% of PD 
cases. Candidate genes linked to genetic 
PD include α-synuclein, leucine rich 
repeat kinase 2 (LRRK2), Parkin, phos-
phatase and tensin homolog (PTEN)-
induced novel kinase 1 (PINK1) , DJ-1 
and ubiquitin carboxy-terminal hydrolase 
L1 (UCH-L1) and several other genes 
(Moore, West et al. 2005). Th e aetiology 
of sporadic PD is unknown, possibly con-
sidered to result from gene-environment 
interactions. According to the „double 
hit hypothesis“ PD is unlikely caused by 
a single factor, but rather results from 
an interaction between multiple genetic 
mutations and/or the combination of a 
mutant gene and an environmental toxin 
(Olanow and Tatton 1999).
Early symptoms of PD include con-
stipation and REM sleep behaviour disor-
der, which are considered to be the initial 
symptoms developing already 10 years 
before onset of disease. The anatomic 
substrate for this disorder lies within the 
brainstem. Olfactory dysfunction and 
impaired sense of smell are also consid-
ered to be the early signs of PD. These 
symptoms do not improve with dopamine 
replenishment therapy and thus could 
be considered to result from an insult to 
non-dopaminergic cells, likely to the nor-
adrenergic, sympathetic and sensory neu-
rons. Th e motor triad leading to diagnosis 
of PD includes resting tremor, rigidity and 
bradykinesia. In later disease stages also 
non-motoric symptoms of autonomic, 
cognitive and psychiatric disturbances 
develop. Advanced symptoms like L-dopa 
refractory motor symptoms, dementia, 
axial symptoms, imbalance, gait problems 
and dysarthria do not refl ect dopaminer-
gic pathology, but rather spreading of pro-
teinaceous intracellular inclusions - Lewy 
Bodies (LB) beyond the nigrostriatal sys-
tem, as there is a gradual loss of L-dopa 
response over the years. Dementia is pres-
ent in 12 to 41% of PD cases and devel-
ops in majority of patients prior to death 
(Ahlskog 2005).
Th e neuro-pathology of PD is charac-
terized by selective degeneration of dopa-
minergic neurons in the SNpc. Although 
the exact mechanism of neurodegenera-
tion in PD is unknown, metabolic com-
promise, excitotoxicity and oxidative 
stress are considered to be the central 
lethal triplet responsible for causing apop-
totic neuronal cell death (Olanow 1999; 
Alexi, Borlongan et al. 2000). Th e patho-
genesis has been proposed to involve oxi-
dative and nitrative stress, excitotoxicity, 
inflammation, mitochondrial dysfunc-
tion and altered proteolysis. These pro-
cesses are part of interrelated cascades 
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4that lead to neuron death through apop-
tosis. It remains unclear which process 
is the initial primary leading cause and 
which is the result of the progression of 
disease (Jenner and Olanow 2006).  Th e 
hallmarks of illness are the presence of 
LB in surviving cells and occurrence of 
reactive microgliosis and to a lesser extent 
astrocytosis (Jenner and Olanow 2006). 
Although LB and α-synuclein (α-syn) 
pathology is present in many neurons, the 
extensive (80%) cell death is present only 
in SN dopaminergic and locus coruleus 
noradrenergic neurons (Jenner and Ola-
now 2006). 
α-Syn is an intracellular protein wide-
ly expressed by the nervous system in pre-
synaptic terminals and nuclear envelope, 
however the exact function of this pro-
tein is unknown. Th e monomeric forms 
of α-syn are considered to play a role in 
dopamine synthesis and content, as well 
as synaptic vesicle functioning and dopa-
mine release (Venda, Cragg et al. 2010). 
Th e formation of the oligomeric and larg-
er aggregated polymeric forms of α-syn 
are considered to be pathologic and are 
the main components of LB in PD. Pro-
tein misfolding and aggregation are nor-
mal processes in a protein`s life, however 
the dysbalance between the processes of 
protein synthesis, folding and clearance is 
considered to be central in the generation 
of pathogenic forms of α-syn  (Lee, Des-
plats et al. 2010; Olanow and McNaught 
2011).  Th e imbalance of increased pro-
duction and impaired clearance lead to 
a vicious cycle of protein accumulation, 
which interferes further with lysosomal 
and proteasomal clearance mechanisms. 
This causes accumulation of pathologic 
proteins and formation of LB inclusions, 
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which impair cell defense mechanisms 
and critical cellular processes, and fi nally 
lead to neurodegeneration (Olanow and 
McNaught 2011). 
Heiko Braak and colleagues suggest 
the “dual-hit hypothesis” as the patho-
genic mechanism initiating PD, whereby a 
neurotropic pathogen (possibly viral) acts 
simultaneously (a) through the nasal route 
via anterograde transport through olfac-
tory bulb, anterior olfactory nucleus to 
olfactory structures of the temporal lobe; 
and (b) via gastrointestinal route through 
submucosal axons of the Meissner´s plex-
us, followed by trans-synaptic transmis-
sion to the parasympathetic neurons of 
the vagal nerve and then through retro-
grade transport to the medulla, pons and 
further to midbrain (Braak, Del Tredici 
et al. 2003; Braak, Ghebremedhin et al. 
2004; Hawkes, Del Tredici et al. 2009). 
Th is hypothesis of transport and spread of 
a neurotropic pathogen from peripheral 
organs to the CNS, is further supported 
by recent fi ndings on PD patients trans-
planted with fetal mesencephalic grafts 
over a decade ago, where α-synuclein 
containing LBs and LB morphology had 
spread, via unknown mechanisms, to the 
previously healthy grafted embryonic 
dopaminergic neurons (Brundin, Li et al. 
2008; Kordower, Chu et al. 2008; Olanow, 
Kordower et al. 2009; Olanow and Prusin-
er 2009). Th ese fi ndings suggest that the 
progression of the disease and synucle-
inopathy could be the result of a “prion-
like” toxic mechanism, whereby the aff ect-
ed neurons of the host transfer the mis-
folded α-synuclein protein to unaff ected 
healthy graft ed neurons (Angot, Steiner et 
al. 2010; Olanow and McNaught 2011). 
5on TRAP symptomatology – Tremor, 
Rigidity, Akinesia and Postural instabil-
ity. Response to levodopa treatment is 
considered to confi rm the clinical diag-
nosis of PD. Magnetic resonance imag-
ing and positron emission tomography 
scans can assist in further diagnosis. Th e 
Unifi ed Parkinson’s Disease Rating Scale 
(UPDRS) is utilized in assessment of PD 
clinical status, disability and impairment 
(Poewe 2009). The evaluation of safety 
and eff ect of a potential therapeutic sub-
stance in clinical trials of PD is based on 
the UPDRS score (Poewe 2009).
1.2.3 Therapeu? c approaches to 
Parkinson’s disease
Th e therapeutic approaches to PD include 
symptomatic and disease modifying - 
neuroprotective and neurorestorative - 
treatments. Symptomatic therapy options 
include levodopa, dopamine agonist, 
combination therapies and surgical treat-
ment (Savitt, Dawson et al. 2006). The 
disease modifying therapeutic approaches 
for PD have mainly focused on promot-
ing neuronal survival and function, inter-
ference with neurotoxic mechanisms, as 
well as cellular replacement strategies 
(Table 1). A vast number of compounds 
have been tested including neurotrophic 
factors, anti-excitotoxins, immunosup-
pressants and -modulators, antioxidants, 
bioenergetic supplements and anti-apop-
totic molecules (Meissner, Frasier et al. 
2011). The most promising therapeutic 
targets for rescuing degenerating neu-
rons are the neurotrophic factors. They 
infl uence cell survival, proliferation, dif-
ferentiation, biochemical functioning, 
as well as neuronal plasticity (Peterson 
and Nutt 2008). Of particular relevance 
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Six clinical stages for PD have been 
described by Braak. 1st and 2nd stage 
- the pre-symptomatic phase - are char-
acterized by inclusion body pathology 
in medulla oblongata/pontine tegmen-
tum and olfactory bulb/anterior olfac-
tory nucleus. During the 3rd and 4th stages 
the SN and other nuclear gray areas in 
midbrain and forebrain are aff ected and 
symptoms appear and develop. During 
the 5th and 6th stage the mature neocor-
tex is involved, and the disease manifests 
(Braak, Del Tredici et al. 2003; Braak, 
Ghebremedhin et al. 2004). A propor-
tion of cases do not fi t this scheme, as it is 
based only on detection of synucleinopa-
thy and not on neuronal loss, although it 
is likely that α-synucleinopathy precedes 
cell death. Criticism on Braak`s staging 
scheme questions the correlation between 
the stages and clinical severity of the dis-
ease, as some Braak 6 stage patients have 
no motor symptoms at all and some stage 
2 patients have intensive motor symp-
toms. Also synuclein pathology cannot be 
regarded as a prognostic factor, as some 
individuals present with synucleinopa-
thy but no PD can be diagnosed. (Burke, 
Dauer et al. 2008) 
1.2.2 Diagnosis of Parkinson’s 
disease
One of the major problems associated 
with PD is the lack of early effi  cient diag-
nosis. Current diagnostic methods allow 
for the detection of the disease only 
when the fi rst symptoms are evident. By 
this stage about 70% of DA neurons in 
the SNpc have been lost. Moreover, fi rst 
symptoms appear when the levels of 
striatal dopamine are reduced by at least 
80%. Clinical diagnosis of PD is based 
6in future PD therapies are GDNF family 
members: GDNF and NRTN (Airaksinen, 
Titievsky et al. 1999; Airaksinen and Saa-
rma 2002). Th ey have been shown to pos-
sess neuroprotective and neurorestorative 
effects on dopaminergic neurons, both 
in vitro and in vivo experimental models 
of PD (Lin, Doherty et al. 1993; Burke, 
Antonelli et al. 1998; Zurn, Widmer et 
al. 2001). Other promising candidates in 
the aspect of disease modifying options 
include MANF (Lindholm, Peranen et 
al. 2008; Lindholm and Saarma 2010), 
CDNF (Lindholm, Voutilainen et al. 2007; 
Lindholm and Saarma 2010) and vascular 
endothelial growth factor A (VEGF-A) 
(Yasuhara, Shingo et al. 2005), all having 
neurorestorative eff ects on DA neurons in 
animal models of PD.  
Swedish company Neuro Nova 
has developed a novel drug candidate 
(sNN0031) for the treatment of moder-
ate to severe stage Parkinson’s disease, 
that is designed to act on neural stem and 
progenitor cells in the brain. In animal 
models of Parkinson’s disease, treatment 
with sNN0031 restores motor function 
and improves neurochemical deficits. 
Th e product is comprised of the naturally 
occurring protein PDGF-BB (platelet-
derived growth factor BB) formulated for 
intracerebroventricular (ICV) delivery 
(www.neuronova.com).
Another exciting strategy to treat PD 
is stem cell therapy, which holds promise 
to one day become an eff ective and rou-
tine approach in the clinic (Arenas 2010). 
Currently two approaches of stem cell 
therapy are being investigated for PD: the 
embryonic stem cells and adult stem cells. 
Embryonic stem cell therapy is limited 
due to ethical and tumorigenic risk issues, 
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thus an alternative approach could be the 
use of adult-derived stem cells includ-
ing bone-marrow derived hematopoietic 
mesenchymal cells, adipose, cord or pla-
centa derived stem cells. Th e adult stem 
cells can be utilized in cell replacement 
therapies to enhance neurogenesis and 
they hold promise in the future replace-
ment therapy for PD. Th ey do not possess 
ethical problems, are autologous - thus no 
immunogenicity problems arise, they can 
be personalized for a specifi c patient and 
as low number of passages are used, no 
problems with tumour development exist 
(Arenas 2010). 
Th e drug discovery fi eld of disease-
modifying therapy for Parkinson`s dis-
ease is progressing rapidly and extensive 
preclinical results are being generated, 
however technical, clinical safety and effi  -
cacy issues for these diff erent approaches 
remain to be solved. Due to the hetero-
geneous nature of Parkinson`s disease, 
a single agent is unlikely to be clinically 
eff ective and rather a combination of mul-
tiple drugs, targeting diff erent pathways 
of disease, will provide clinical benefi t for 
the patients in the future. 
1.2.4 Animal models of Parkinson’s 
disease
PD models have been developed to assist 
in understanding the pathogenic process-
es, molecular and biochemical pathways 
affected in PD and for testing possible 
therapeutic approaches. In principle these 
models should resemble the characteris-
tic features seen in PD patients, includ-
ing normal number of DA neurons at 
birth and onset of progressive neurode-
generation in late-adulthood, loss of DA 
neurons leading to symptoms of motor 
7dysfunction, including L-dopa respon-
sive movement disorder – bradykinesia, 
rigidity and resting tremor (Beal 2001; 
Orth and Tabrizi 2003; Dawson, Ko et 
al. 2010). In addition Lewy body-like 
inclusions should be present. Th e model 
should be followable in a relatively short 
time for rapid screening and should be 
cost-eff ective (Beal 2001; Orth and Tabrizi 
2003; Dawson, Ko et al. 2010). Since the 
exact aetiology of PD is unknown and 
the pathogenesis is likely to be multifac-
torial and heterogeneous, the establish-
ment of disease models, displaying all 
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features of clinical PD, has been diffi  cult. 
Th e existing models of PD could be fur-
ther classifi ed into two broad categories: 
toxin-induced models and genetic ani-
mal models. Three main toxin-induced 
models have been described: 6-hydroxy-
dopamine (6-OHDA), 1-methyl-4-phe-
nyl-1,2,3,6 tetrahydropyridine (MPTP) 
and rotenone. Th e correlation and resem-
blance of diff erent animal toxin models to 
the clinical PD in humans depends on the 
location of the lesion, percentage of dopa-
mine depletion in the striatum and the 
behavioural test which are used to evalu-
Table 1. Disease-modifying therapy of Parkinson`s disease.
THERAPY PROS CONS
Neurotrophic 
factors
Neuroprotection; neurorestoration; 
diff erentiation; indirect eff ects on 
infl ammatory and vascular systems.
Diffi  culties in delivery to brain; 
systemic side-eff ects; clinical 
trial results unclear. 
Embryonic 
mesencephalic 
graft  transplants
Functional reconstruction; synaptic 
connectivity; dopamine release; 
improved motor function. 
Ethical issues; limited tissue 
availability and quality; 
variable results; dyskinesias; 
neuroinfl ammation.
Human embryonic 
stem cells
Possibility to diff erentiate to 
dopaminergic cells; functional 
reconstruction.
Ethical issues; 
tumour development; 
immunosuppression needed; 
possibly α-syn transmission 
from host to cells.
Adult stem cells Possibility to diff erentiate to either 
glial or neuronal cells to induce 
functional reconstruction; no ethical 
concerns; both autologous (no need 
for immunosuppression, personalized) 
and allogeneic; unlimited amounts of 
standardized cells. 
Safety issues unclear; technical 
issues in production; in 
preclinical phase; possibly 
α-syn transmission from host 
to cells.
Antioxidants, 
bioenergetics 
supplements
Decrease free oxidative radicals; 
neuroprotection from oxidative stress; 
slow the progression of disability.
Clinical benefi t unclear; 
unlikely to be eff ective as 
monotherapy.
Anti-infl ammatory 
molecules
Decrease the pathologic infl ammatory 
response.
Clinical benefi t unclear; 
unlikely to be eff ective as 
monotherapy
Anti-apoptotic 
molecules
Inhibit neuronal apoptotic cell death; 
neuroprotection.
Clinical benefi t unclear; 
unlikely to be eff ective as 
monotherapy
8ate the extent of the lesion (Deumens, 
Blokland et al. 2002). 
Th e 6-OHDA was the fi rst described 
toxin model for PD. Injection of 6-OHDA 
to SN leads to selective accumulation 
of the toxin in DA neurons, resulting in 
dopaminergic cell death due to oxidative 
stress. In rats the lesion can be followed by 
behavioural analysis of rotational activity 
in response to amphetamine or apomor-
phine. Despite the visible motor defi cit, 
there are no LB-like inclusions present 
(Beal 2001; Orth and Tabrizi 2003). Sys-
temically administered 6-OHDA does not 
cross the BBB, thus stereotactical intra-
cranial delivery of the toxin has to be uti-
lized. Several diff erent 6-OHDA lesions 
have been described based on the site 
of the lesion, the extent of nigrostriatal 
damage and dopamine depletion. In rats 
at least 80% DA depletion is required to 
overcome compensatory dopaminergic 
mechanisms which can complicate the 
interpretation of eff ects (Deumens, Blok-
land et al. 2002).  
In general, three sites of lesion are 
mostly used, with both unilateral and 
bilateral injections. Injection of 6-OHDA 
to the medial forebrain bundle (MFB) 
– the most widely used model - causes 
almost total destruction of the SN and 
VTA neurons and leads to total deple-
tion of DA in the CPu, super-sensitivity 
of postsynaptic DA receptors in the CPu 
and characteristic turning behaviour in 
response to D-amphetamine and apomor-
phine (Deumens, Blokland et al. 2002). 
Th is model resembles most the advanced 
stages of PD. More selective injection of 
6-OHDA to the nigrostriatal part of the 
MFB produces a milder and clinically 
more relevant lesion, however achieve-
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ment of this is technically demanding 
(Deumens, Blokland et al. 2002). Th e sec-
ond approach is the injection of 6-OHDA 
to the SN of rats, which leads to 88% cell 
loss in the SN, however also 30% cells loss 
in VTA neurons occurs. Injection to this 
area is also technically difficult, due to 
the small size of the SN (Deumens, Blok-
land et al. 2002). Th e third site of injec-
tion, considered to be the best accessible 
and reproducible site, is the dorsal stria-
tum. Injection to the ventrolateral or dor-
somedial site of STR leads to either cell 
loss only in the SN or both SN and VTA, 
respectively (Deumens, Blokland et al. 
2002). Th e partial 6-OHDA striatal tox-
in model represents milder and delayed 
degeneration of the SN neurons. Stan-
dardized injection to this site causes selec-
tive destruction of DA axons and termi-
nals around the injection site, leading to 
protracted cell death of the accompanying 
DA cell bodies. Th is model closely resem-
bles the early stages of PD in humans 
(Björklund, Rosenblad et al. 1997). 
In general, the 6-OHDA striatal 
lesion is possibly the best model, as it 
is initiated by synaptic and retrograde 
degeneration of axons leading to neuronal 
cell death, recapitulating most the process 
of PD pathology in humans. Using higher 
doses of toxin or multiple injection sites, 
the extent and severity of the lesion can 
be regulated. In the case of toxin injection 
to SN or MFB the pathology does not cor-
relate very well to the human PD, as the 
initial degeneration of neuronal cell bod-
ies is rapid and severe, with axon degen-
eration being rather a secondary event. In 
conclusion, the 6-OHDA model does not 
resemble completely the pathology and 
symptomatology of human PD, due to the 
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human PD, as in mice it does not induce 
nigral cell loss, but rather represents a 
model of dopaminergic dediff erentiation 
due to loss of dopaminergic phenotype. In 
addition the nature of the insult is acute 
and non-progressive, other non-dopami-
nergic systems are uninvolved and there 
is lack of LB pathology.   
Th e third toxin model of PD is based 
on a naturally occurring compound – 
rotenone, used widely as a pesticide. Fol-
lowing intravenous infusion, rotenone is 
transported to the intracellular compart-
ment, where it inhibits the mitochondrial 
complex I. This highlights the selective 
vulnerability of the nigral neurons to oxi-
dative stress as rotenone inhibits the com-
plex I mechanism uniformly in all brain 
cells (Beal 2001; Orth and Tabrizi 2003). 
Although it has been thought that rote-
none is poorly taken up by the gastroin-
testinal tract, recently it was shown that 
intragastrical administration of rotenone 
causes PD-like symptomatology in mice. 
Th is process models the human patholog-
ical staging of PD and supports the alter-
native trans-synaptic toxin uptake mech-
anism, whereby enteric neurons facilitate 
the spread of environmental neurotoxic 
molecules and thus contribute to the 
development of PD (Pan-Montojo, Anich-
tchik et al. 2010). The rotenone model 
meets most of the criteria for an excel-
lent model of PD, including motor defi -
cits, selective degeneration of SN neurons, 
as well as presence of LB-like inclusions, 
however variability issues in individual 
rat susceptibility have been reported (Beal 
2001; Orth and Tabrizi 2003).  
An interesting model, in regard to the 
infl ammatory aspect of PD pathology, is 
the lipopolysaccharide model (LPS). LPS 
acute non-progressive nature of insult, 
lack of LB pathology and tremor - the car-
dinal symptom in disease, as well as lack 
of other non-dopaminergic systems and 
brain areas - characteristic to late stages of 
disease (Schober 2004). 
The most convenient and best 
described PD model is the MPTP toxin 
model. MPTP rapidly crosses the BBB 
and is converted to its active metabolite 
– 1-methyl-4-phenylpyridinium (MPP⁺) 
by a catecholamine degrading enzyme 
- monoamine oxidase B. MPP⁺ is then 
transported into the cells by the dopa-
mine transporter, where it inhibits the 
complex I of the mitochondrial respira-
tory chain or is taken up by the vesicular 
monoamine transporter to the synaptic 
vesicles. Th e MPTP model highly resem-
bles the classical features of PD, but diff ers 
due to the acute onset of the process and 
due to the lack of LBs (Beal 2001; Orth 
and Tabrizi 2003). Th e MPTP model has 
been well established also in primate PD 
studies. The neurotoxic doses of MPTP 
in primates are up to 50-fold lower than 
in mice, due to diff erences in sensitivity. 
In primates the MPTP-induced lesion is 
long-lasting and permanent and can be 
treated with L-DOPA. Th e motor defects 
in primates resemble the PD symptoms 
in man, most prominently akinesia and 
rigidity and seldom hand tremor (Ger-
lach and Riederer 1996). Evaluation and 
comparison of the clinical defect in pri-
mate MPTP studies is a question of con-
cern, as several different clinical rating 
scores (CRS) have been described for 
evaluation of the toxin model and thera-
py eff ect (Imbert, Bezard et al. 2000). In 
conclusion, controversy exists in regard to 
MPTP being a good model representing 
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is an endotoxin derived from gram nega-
tive bacteria, which induces stimulation 
of both peripheral immune cells and CNS 
glial cells (especially microglia) and leads 
to the release of immunoregulatory mol-
ecules and free radicals. Th e LPS model 
causes indirect  infl ammation-mediated 
neurodegeneration (Dutta, Zhang et al. 
2008), which can be useful in modelling 
the human disease as PD is also accompa-
nied by neuroinfl ammation. 
Several animal models representing 
the genetic basis of PD have been devel-
oped, including the α-synuclein, DJ-1, 
PINK-1, Parkin, LRRK2 and mitopark 
mouse models (Burke 2007). Trans-
gene over-expressing mutants have been 
generated for the autosomal-dominant 
genes α-synuclein and LRRK2, as well as 
knockout models for autosomal-recessive 
genetic forms: Parkin, DJ-1 and PINK-
1. Although these models exhibit several 
useful features for studying PD pathol-
ogy, such as presence of LB morphology 
in most of the models, they are limited 
due to lack of meaningful DA neurode-
generation, vague motor symptomatol-
ogy, and slow progression of pathology 
(Dawson, Ko et al. 2010; Meissner, Fra-
sier et al. 2011). Th e artifi cial MitoPark 
mouse model targets the mitochondrial 
dysfunction aspect in PD pathology and 
cell type-specific inactivation of mito-
chondrial transcription factor A leads 
to adult-onset, progressive, severe DA 
cell death accompanied by motor defi-
cits responding to L-DOPA treatment 
(Ekstrand and Galter 2009). Recently a 
mouse model lacking the DJ-1 gene in all 
cells and RET receptor selectively in the 
DA neurons has been generated, showing 
accelerated selective age-associated loss of 
SN cell bodies, as compared to either sin-
gle mutant alone (Aron, Klein et al. 2010). 
In a more recent study LRRK2 overex-
pression together with A53T mutation in 
α-synuclein rendered signifi cant neuro-
degeneration and cell loss in SNpc (Lin, 
Parisiadou et al. 2009). Recently, a model 
with targeted overexpression of human 
wild-type α-synuclein in the nigrostriatal 
system, using adeno-associated viral vec-
tors, has been established. Overexpression 
of α-syn causes progressive degeneration 
of the nigral dopamine neurons and the 
development of axonal pathology in the 
striatum (Decressac, Ulusoy et al. 2011). 
The genetic mouse models are the 
most versatile of the PD animal models 
as diff erent systemic aspects can be stud-
ied, they exhibit α-synuclein pathology 
and some motor defects, but the aggre-
gation of α-synuclein is independent of 
progressive neurodegeneration and there 
is no α-synuclein pathology present in the 
brainstem and nucleus vagus - the pos-
tulated early locations of PD pathology 
and spread (Dawson, Ko et al. 2010). In 
conclusion, no ideal animal model for PD 
exists, they all exhibit benefi ts and limita-
tions and the selection of a suitable model 
should depend on the question under 
consideration.
1.3 Neurotrophic factors
Neurotrophic factors have significant 
physiological roles in neuronal survival, 
functioning and maintenance of the ner-
vous system, from development to adult-
hood.  Th ey induce growth, diff erentiation 
and survival of neurons, as well as neuro-
nal progenitor cells. Since the discovery 
of nerve growth factor (NGF) by Levi-
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Montalcini more than 50 years ago (Levi-
Montalcini and Cohen 1956; Levi-Mon-
talcini 1987) the classical „target-derived“ 
neurotrophic factor hypothesis has been 
well established (Fig.2). Th e concept states 
that during neural development neurons 
are over-produced in excess amounts, the 
presynaptic neurons compete for limited 
amounts of growth factors synthesized by 
post-synaptic targets, which determine 
the fi nal number of neurons able to make 
synaptic connections in tissues, while the 
neurons not receiving neurotrophic sup-
port are removed by programmed cell 
death (Oppenheim 1991). 
However, at present the NTF inter-
actions are considered to be much more 
complex. A single NTF infl uences a vari-
ety of neuronal types and non-neuronal 
cells, certain types of neurons can be 
dependent on multiple different neu-
rotrophic factors, different NTFs show 
overlapping patterns of activities through 
convergence of intracellular signal trans-
duction pathways, or sharing of receptors 
and subunits (Korsching 1993).  In CNS 
the trophic factors are mostly synthesized 
by neurons and glial cells, and they act 
in both autocrine and paracrine fashion. 
Traditionally the NTFs have been con-
sidered to be produced and released by 
the target cells, internalized through the 
nerve terminals via specifi c receptors and 
the ligand-receptor complex within the 
endosomes is transported retrogradely 
to the cell body where the signalling 
Figure 2. Schematic presentation of the target-derived neurotrophic factor (NTF) hypothesis, 
stating that during development neurons are produced in excess amounts. Axons of developing 
neurons grow toward and compete for limited amounts of NTFs secreted by target tissues. Th e 
neurons which achieve support are able to make synaptic connections in tissues, while neurons 
which fail to receive support degenerate and are removed by apoptosis. Author: Maarja Kotkas.
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mechanisms are initiated. Th e transport 
mechanisms seem more complex and also 
anterograde axonal transport has been 
described. Strictly retrograde signalling 
has been shown for NGF, other NTFs 
such as BDNF, IGF-I, FGF-2 and GDNF 
can be transported both retrogradely and 
anterogradely to and from target neurons, 
as well as through neurons by transcyto-
sis, indicating that the same NTF can be 
utilized by more than one neuron or glial 
cell (von Bartheld, Wang et al. 2001). In 
addition, the availability and interconnec-
tions of diff erent NTFs seem to be more 
complex, as recycling, storage and pools 
of factors have been described, in addition 
to de novo synthesis of NTFs upon need 
(von Bartheld, Wang et al. 2001).
Classically three families of neuro-
trophic factors have been characterized: 
the neurotrophins, GDNF family ligands 
(GFLs) and the neuropoietic cytokines. 
Recently a new class of potent neuro-
trophic factors has been discovered: the 
CDNF/MANF family of neurotrophic fac-
tors (Lindholm and Saarma 2010). How-
ever, other growth factors like members of 
the FGF family, IGF family, TGF-β family 
and VEGF-A, have been shown to possess 
neurotrophic properties. 
Members of the neurotrophin fam-
ily include the fi rst characterized neuro-
trophic factor – NGF, BDNF and neuro-
trophins-3, -4 (NT-3,-4). Th ey function in 
maintaining viability of sensory and sym-
pathetic neurons of the PNS and several 
types of CNS neurons, like basal forebrain 
and striatal cholinergic, cortical, and reti-
nal ganglion cells as well as precursor and 
neural crest cells during development 
(Huang and Reichardt 2001). 
Th e neuropoietic cytokines, initially 
characterized to have a central role in the 
immune system, have been shown to act 
also in the nervous system. Th e main neu-
ropoietic cytokines are leukemia inhibito-
ry factor (LIF), ciliary neurotrophic factor 
(CNTF) and interleukin-6 (IL-6). During 
development they regulate self-renewal 
of neural stem cells and determine the 
cell fate, participate in the developmen-
tal switch from neurogenesis to gliogen-
esis and in differentiation of astrocytes 
from neural progenitors (Bauer, Kerr et 
al. 2007). Neuropoietic cytokines regu-
late the survival of embryonic sensory 
neurons and most importantly postnatal 
spinal motor neurons. They have been 
shown to play a role in injury processes 
like peripheral nerve and spinal cord 
injury, autoimmune demyelinating dis-
orders, as well as modulation of endoge-
nous repair processes. Th ey function both 
directly and indirectly by up-regulating 
the expression of neuropeptides and other 
neurotrophic factors (Bauer, Kerr et al. 
2007).  
Th e newest class of neurotrophic fac-
tors is the CDNF/MANF family. These 
two factors have been shown to have dual 
roles as extracellular NTFs and endoplas-
matic reticulum resident cytoprotective 
proteins. Great interest has arisen due to 
their ability to promote the survival of 
midbrain dopamine neurons. MANF and 
CDNF have been shown to have neuro-
protective and neurorestorative properties 
in animal models of Parkinson’s disease. 
These factors may function as target-
derived NTFs for mDA neurons, but anal-
ysis of the respective knockout animals 
is needed to answer this question (Lind-
holm and Saarma ; Lindholm, Voutilainen 
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et al. 2007; Lindholm, Peranen et al. 2008; 
Voutilainen, Back et al. 2009). 
In adulthood the focus of NTFs is 
shifted from target-derived survival to 
the regulation of neuronal phenotype 
and function. In normal adult brain they 
have been shown to modulate long-term 
potentiation (LTP), learning and memory. 
NTFs function in the modulation of neu-
ronal plasticity, infl uencing cell body size, 
dentritic arborization, terminal sprouting, 
gene expression and also in adult main-
tenance of neurons. They also function 
in neuroprotection and neural repair in 
response to axotomy, excitotoxicity, toxins 
and other types of injury and insults, such 
as ischemia, trauma and degenerative dis-
eases (Sofroniew, Howe et al. 2001).  As 
NTFs have been shown to infl uence neu-
roprotection, neurorestoration and bio-
logical functioning, there has been great 
interest in the therapeutic potential of 
these factors on various diseases.
1.4 GDNF family ligands
1.4.1 Expression and func? ons
GDNF family is comprised of four mem-
bers: GDNF, NRTN, artemin (ARTN) and 
persephin (PSPN) (Airaksinen and Saa-
rma 2002; Smidt and Burbach 2007).Th e 
GFLs are distant members of the TGF-β 
superfamily, being characterized by seven 
conserved cysteins with identical spacing 
and homodimeric cysteine-knot proteins 
with similar spatial structure. Th ey func-
tion as secreted proteins and are synthe-
sized in the form of prepro-precursors. 
Th ey bind to specifi c co-receptors known 
as GDNF-family receptor-α (GFRα) and 
signal through common transmembrane 
receptor tyrosine kinase  RET (Rear-
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Figure 3. Schematic presentation of the GDNF family of neurotrophic growth factors and recep-
tors. Reprinted by permission from Macmillan Publishers Ltd. (Nature Reviews Neuroscience 3, 
383-394) Copyright © 2002.
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ranged during Transfection). Th e ligand 
specifi city of GFLs is determined by bind-
ing to four different GFRα receptors: 
GFRα1 for GDNF, GFRα2 for NRTN, 
GFRα3 for ARTN and GFRα4 for PSPN. 
Crosstalk between the ligands and recep-
tors has been shown for NRTN, ARTN 
and PSPN to GFRα1 and GDNF to 
GFRα2 and GFRα3 (Fig.3). 
GFLs have diverse expression pat-
terns in the CNS and PNS. Th ey function 
in the maintenance of sympathetic, para-
sympathetic, enteric, somatic sensory, 
cortical, motor and dopaminergic neu-
ronal systems (Airaksinen and Saarma 
2002).  
In sympathetic ganglia (SG) RET 
receptor expression is widespread at 
embryonic day E11.5 and by birth RET, 
GFRα2 and GFRα3 expression is restrict-
ed to a subpopulation of sympathetic neu-
rons.  RET knockout (KO) mice exhibit 
30% reduction in sympathetic ganglia 
size and  misplacement of superior sym-
pathetic ganglia (SCG), due to defective 
precursor migration to ganglionic site and 
increased apoptosis during development. 
ARTN and GFRα3 KO mice have reduced 
cervical and thoracic ganglia size and dis-
placement. GFRα3 mutant mice have 50% 
cell loss in SCG neurons at birth due to 
defects in migration, proliferation and 
survival. NRTN and GFRα2 mutant mice 
have serious defects in the parasympa-
thetic nervous system, but no signifi cant 
changes in the sensory or sympathetic 
phenotype (Rossi, Luukko et al. 1999). Ret 
and GFRα3 mutant mice also have defects 
in neurite outgrowth (Ernsberger 2008).
GFLs support the survival and target 
innervation of a subpopulation of prima-
ry sensory neurons postnatally. In embry-
onic stages RET is expressed in a small 
number of neurons in dorsal root ganglia 
(DRG). RET and GFRα receptor expres-
sion is increased at birth, and in adult 
60% of DRG neurons express RET. In 
GFL mutants cell death is not prominent 
in sensory ganglia and no signifi cant neu-
ronal loss is observed. Th ey aff ect rather 
mechanical and thermal responsiveness of 
sensory neurons and induce neurite out-
growth (Ernsberger 2008). 
GDNF is a target-derived survival 
factor for a subpopulation of motor neu-
rons, as the GDNF deficient mice have 
20-40% less spinal and cranial motor 
neurons. By E15 GDNF is expressed in 
all muscles. Most motoneurons in the spi-
nal cord express the RET receptor. Dur-
ing development and postnatally GDNF 
regulates pool-specific cell migration, 
axonal outgrowth, branching and synaptic 
connectivity of motor neurons (Kanning, 
Kaplan et al. 2010). GDNF is secreted 
by both muscles and astrocytes. Over-
expression of GDNF by astrocytes results 
in increased number of motoneurons due 
to rescue from programmed cell death 
(PCD) and this astrocyte-derived GDNF 
can promote long-term motor neuron 
survival following axotomy (Zhao, Alam 
et al. 2004).
GDNF signalling is required for 
migration and proliferation of parasym-
pathetic neuronal precursors during early 
embryonic development. NRTN role in 
parasympathetic ganglia is to support 
postnatal target innervation and main-
tain their phenotype and  trophic status. 
Th us there is a shift  from GDNF to NRTN 
signalling in developing parasympathetic 
neurons. GDNF also promotes the migra-
tion, proliferation, survival and diff eren-
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tiation of enteric precursors. RET, GFRα1 
and GDNF KO mice all lack enteric 
neurons in the gut distal to the stom-
ach. NRTN supports enteric innervation 
and regulates neurotransmitter release 
in enteric neurons. A similar shift  from 
GDNF to NRTN, as seen in parasympa-
thetic neurons, occurs also in enteric neu-
rons (Baloh, Enomoto et al. 2000; Airak-
sinen and Saarma 2002).
Due to the wide range of functions 
the GFLs have been implicated to play 
a role in motor neuron disease, sensory 
regeneration, neuropathic pain, isch-
emia, epilepsy, addiction and Parkinson’s 
disease (Airaksinen and Saarma 2002). 
Expression outside the nervous system 
has also been described, thus GFLs pos-
sess also non-neuronal properties, such 
as regulation of ureteric branching during 
kidney development and spermatogenesis 
(Sariola and Saarma 2003).  
1.4.2 Signalling 
Th e RET receptor is a single-pass trans-
membrane protein containing four cad-
herin-like domains and a cysteine-rich 
domain in the extracellular part, and an 
intracellular tyrosine kinase domain. 
RET is the only receptor tyrosine kinase, 
which does not bind its ligand directly, 
but requires a co-receptor - GFRα - for its 
activation. GFRα receptors are GPI-linked 
receptors located in lipid raft s on cell sur-
face. Th ey contain three globular cysteine-
rich domains (except for GFRα4 having 
only two domains). Homodimeric ligands 
bind fi rst to monomeric or dimeric GFRα 
receptors, this complex interacts in a Ca²⁺ 
dependent manner with the extracellular 
domains of two RET molecules, induc-
ing the dimerization and phosphoryla-
tion of the intracellular tyrosine kinase 
domains which then transphosphorylate 
each other on crucial residues. On the 
intracellular part of RET at least six phos-
photyrosine residues (Tyr687, Tyr905, 
Tyr981,Tyr1015, Tyr1062 and Tyr1096) 
act as docking sites for diff erent proteins, 
triggering activation of intracellular sig-
nalling cascades like MAPK, PI3K/AKT, 
JUN, Src, PLCγ, SHP2, thereby contribut-
ing to neuronal survival, neuritogenesis 
and neurotransmission (Airaksinen and 
Saarma 2002; Runeberg-Roos and Saarma 
2007).
Malfunctioning of the RET recep-
tor leads to several inherited diseases. 
Inactivating mutations of RET cause 
Hirschsbrung’s disease, which is charac-
terized by aganglionic megacolon. The 
activating mutations of RET lead to dif-
ferent types of multiple endocrine neo-
plasia (MEN)2 cancer syndromes, which 
are classified into three subgroups. The 
MEN2A syndrome is characterized by 
medullary thyroid carcinoma (MTC), 
phaeochromocytoma of adrenal medulla 
and hyperparathyroidism. Th is variant is 
mainly due to abnormal formation of S-S 
bridges between the extracellular domains 
of two RET molecules. Th e MEN2B syn-
drome presents with MTC, phaeochro-
mocytoma accompanied by marfanoid 
habitus, thickening of the corneal nerve 
and ganglioneuromatosis of the buccal 
membrane and gastrointestinal (GI) tract. 
Th is syndrome is in most cases caused by 
a single germline mutation resulting in 
substitution of threonine for methionine 
at codon 918. Th ese activating mutations 
in the intracellular kinase domain lead to 
activation of signalling cascades either as 
monomers or associated dimers. Th e third 
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syndrome - familial medullary thyroid 
carcinoma (FMTC) manifests with only 
MTC (Runeberg-Roos and Saarma 2007). 
GFLs can also signal independently 
of RET using the neural cell adhesion 
molecule (NCAM) (Paratcha, Ledda et al. 
2003) and this signalling is strictly GFRα1 
dependent (Sjostrand and Ibáñez 2008). 
Alternative signalling by integrin β-1 and 
N-cadherin has been suggested, but the 
evidence is still indirect (Cao, Yu et al. 
2008; Cao, Li et al. 2010). Recently it was 
shown that heparan sulfate proteoglycan 
syndecan-3 is a novel receptor for GDNF, 
neurturin, and artemin. GFL-syndecan-3 
interaction mediates both cell spreading 
and neurite outgrowth with the involve-
ment of Src kinase activation (Gerhardt, 
Cass et al. 1999). In addition, GDNF pro-
motes migration of cortical neurons in a 
syndecan-3-dependent manner (Bespalov, 
Sidorova et al. 2011). 
1.4.3 GFLs roles in the 
dopaminergic system 
GDNF`s role as a neurotrophic factor for 
embryonic midbrain dopaminergic neu-
rons in vitro was first described by Lin 
et al (Lin, Doherty et al. 1993). In vivo 
GDNF has been shown to support the 
DA neurons during the period of post-
natal cell death and in adults it promotes 
survival, as well as regrowth and recovery 
following damage by MPP⁺ and 6-OHDA 
(Tomac, Lindqvist et al. 1995; Hou, Lin et 
al. 1996; Burke, Antonelli et al. 1998; Egg-
ert, Schlegel et al. 1999; Gerhardt, Cass et 
al. 1999; Kramer, Goldman et al. 1999).
Intracranial administration of GDNF to 
unlesioned animals causes behavioural 
effects of increased locomotor activity 
due to raised levels and turnover of brain 
monoamines including DA, as well as 
dose-dependent morphological changes 
due to increased cell size, axonal out-
growth and growth cone-like profiles 
(Table 2). Injection of GDNF into SN or 
cerebral ventricles is accompanied by 
side-eff ects, such as weight loss (Lapchak, 
Miller et al. 1996).
Extensive in vivo studies of GDNF eff ects 
on the dopaminergic system have been 
carried out on lesioned animals (Table 3). 
Many diff erent approaches to investigate 
GDNF-mediated neuroprotection and 
neurorestoration in vivo have been uti-
lized:  
a) different lesion models including 
6-OHDA, MPTP, partial lesions vs 
extensive lesions
b) timing of GDNF administration 
including before, during and follow-
ing the lesions
c) diff erent routes and sites of adminis-
tration including intranigral, intra-
striatal, intraventricular or via cere-
brospinal fl uid
d) diff erent doses and means of admin-
istration, including single dose, single 
administration, diff erent doses, con-
tinuous administration, mesence-
phalic graft s, lenti- and adeno-associ-
ated virus mediated administration or 
genetically engineered cells
e) different animal models including 
mice, rats and non-human primates
These in vivo experiments have estab-
lished a clear conclusion that GDNF 
exhibits neuroprotective and neurorestor-
ative effects in animal models of PD. 
GDNF induces behavioural improvement 
by prevention of lesion-induced motor 
defi cits, as well as morphological changes 
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Table 2. Experiments with intracranial delivery of GDNF to intact brain in animals.
INTACT BRAIN EFFECT Reference
Single injection ↑motor activity, ↑amphetamine turning 
behaviour, 
↓food & water intake, 
↓body weight, 
TH+ neurite sprouting, 
↑TH staining, 
↑DA turnover, 
↑DA & metabolite levels, 
↑DA release, 
↑TH & ↑ERK1/2 phosphorylation
(Hudson, Granholm 
et al. 1995; Hebert, 
Van Horne et al. 
1996; Martin, Miller 
et al. 1996; Hebert 
and Gerhardt 1997; 
Lapchak, Miller et al. 
1997; Xu and Dluzen 
2000; Salvatore, Zhang 
et al. 2004)
Continuous expression by 
lentiviral vector
Initially: 
↑DA turnover, 
↑function
In 6-weeks: 
↑TH mRNA
↓TH protein, 
↓TH activity, 
normal DA 
(Rosenblad, 
Georgievska et al. 
2003; Georgievska, 
Jakobsson et al. 2004; 
Georgievska, Kirik et 
al. 2004)
Primates
Gash to SN
Kordower to SN and STR
Grondin to lateral 
ventricle
Eslamboli to STR
↑motor function, 
↑DA levels, release,
↑TH activity, 
↑DA metabolites,
↓DA levels
(Gash, Zhang et al. 
1995; Kordower, 
Emborg et al. 2000; 
Grondin, Cass et al. 
2003; Eslamboli, 
Georgievska et al. 
2005)
expressed in protection and preservation 
of DA neuronal cell bodies and axon ter-
minals, increased DA metabolism, as well 
as increased TH and dopamine levels in 
the striatum. 
The in vivo neurorestorative and 
regenerative potential of GDNF – in case 
the factor is administered to the previous-
ly compromised midbrain - is of central 
clinical relevance (Tomac, Lindqvist et al. 
1995; Kirik, Rosenblad et al. 2000; Kirik, 
Georgievska et al. 2001).  In this paradigm 
GDNF influences the whole nigrostria-
tal system by restoring the phenotype of 
DA neurons. It functions by rescuing the 
TH-positive neurons, increasing cell body 
size, axonal sprouting and the number of 
axonal terminals, as well as by elevating 
tissue levels of DA and its metabolites, 
DA turnover and release. Positive results 
with GDNF were also gained on primate 
studies, where GDNF showed remark-
able improvement in hemiparkinsonism 
in MPTP treated monkeys via different 
routes of administration (Gash, Zhang 
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et al. 1996; Zhang, Miyoshi et al. 1997; 
Grondin, Zhang et al. 2002). 
The site of the lesion and admin-
istration of GDNF protein is of central 
importance in correlating the in vivo ani-
mal studies with possible clinical aspects. 
Two sites of administration for GDNF in 
brain have been mainly used: the intra-
nigral and intrastriatal delivery. Appli-
cation of GDNF to SN leads to effi  cient 
neuroprotection and neurorestoration of 
SN cell bodies, however degeneration of 
the nerve terminals is not prevented and 
fiber sprouting takes place around the 
nigral neuron cell bodies. Also functional 
recovery is not as evident, due to lack of 
regenerating axons. Application of GDNF 
to the SN also causes quite serious side-
eff ects, as chronic infusion of GDNF to 
SN has been shown to cause signifi cant 
weight loss in rats (Manfredsson, Tumer 
et al. 2009). Application of GDNF to the 
striatum leads to sparing of striatal fi bers. 
In addition, protection of TH-positive 
nigral cell bodies and fi ber sprouting also 
occurs inside the striatum and globus 
pallidus. In the case of striatal delivery 
functional recovery of motor behaviour 
is remarkable (Kirik, Georgievska et al. 
2004).  
Another aspect to be kept in mind, 
regarding the site of administration, 
is the anterograde-retrograde trans-
port of GDNF in the dopaminergic sys-
tem. Both ways of transport have been 
described (Kordower, Emborg et al. 2000; 
Ai, Markesbery et al. 2003; Georgievska, 
Jakobsson et al. 2004; Ciesielska, Mitter-
meyer et al. 2011).
1.4.4 Transgenic mouse models of 
GDNF and RET
To validate the physiological relevance of 
GDNF eff ects on the DA system, several 
transgenic models of GDNF signalling 
pathway have been generated. 
Studies on GDNF, GFRα1 and RET 
KO animals have shown that DA neurons 
are not dependent on GDNF signalling 
during embryonic development, as these 
animals exhibit normal number of DA 
neurons in the ventral midbrain (Moore, 
Klein et al. 1996; Pichel, Shen et al. 1996; 
Sanchez, Silos-Santiago et al. 1996; Gran-
holm, Mott et al. 1997; Granholm, Sriv-
astava et al. 1997; Cacalano, Farinas et al. 
1998; Enomoto, Araki et al. 1998). Post-
natal-studies of the DA system from these 
KO animals are not possible, as they die 
aft er birth due to renal agenesis. 
GDNF seems to function as a target-
derived neurotrophic factor for the DA 
neurons postnatally during the natural cell 
death period (Burke, Antonelli et al. 1998; 
Burke 2006). Th is cell death is restricted 
to the first early phase of postnatal cell 
death and lasts till P7, after which the 
DA neurons become dependent on oth-
er factors (Oo, Kholodilov et al. 2003). 
Th e postnatal GDNF dependence of DA 
neurons has been further confirmed by 
transplantation studies using fetal ventral 
mesencephalon from GDNF null mice to 
wild type striatum, which impaired post-
natal DA neuron survival (Granholm, 
Reyland et al. 2000). Further generation 
of mice selectively over-expressing GDNF 
in striatum showed that GDNF is indeed 
important for early postnatal cell death, 
as these animals have increased number 
of SN DA neurons following this period. 
However, this increase does not persist 
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into adulthood and the number of SN DA 
neurons is not increased in adult animals, 
although there is increased number of 
VTA neurons (Oo, Kholodilov et al. 2003) 
Studies on DA system of aged het-
erozygous GDNF animals, who exhibit 
about 50% decrease in the level of GDNF 
protein, have suggested a role for GDNF 
in long-term maintenance of DA system 
(Gerlai, McNamara et al. 2001; Airavaara, 
Mijatovic et al. 2006; Boger, Middaugh 
et al. 2006; Airavaara, Tuomainen et al. 
2007). 
Although GFRα1 receptor has been 
conditionally deleted during late enteric 
nervous system development, which lead 
to widespread death of enteric neurons 
and agangliosis (Uesaka, Jain et al. 2007), 
this receptor has not yet been deleted 
from the midbrain DA neurons.   
Kholodilov et al have generated mice, 
which selectively over-express GDNF in 
the striatum, cortex and hippocampus. 
These animals show increased number 
of SN DA neurons after the first phase 
of cell death, however not in adulthood 
(Kholodilov, Yarygina et al. 2004). Adult 
animals do not have increased dopami-
nergic innervation of striatum, but exhib-
it increased number of VTA neurons and 
increased innervations of cortex. They 
also show increased locomotor activity 
to amphetamine (Kholodilov, Yarygina et 
al. 2004).  Results on the over-expression 
of GDNF in cells that naturally do not 
express GDNF should be very carefully 
interpreted. For example over-expressing 
GDNF under a testis specifi c promoter led 
to male infertility and testicular tumours 
in older age (Meng, Lindahl et al. 2000).
RET conditional knockout mice 
have provided additional information 
on the role of GDNF signalling pathway 
in the maintenance of the dopaminergic 
system. RET cKO mice created by Jain et 
al. (2006) showed no changes in DA cell 
number, size and in DA levels in the SN 
and VTA until 1 year of age and therefore 
the authors concluded that RET signalling 
is not critical for normal physiology of 
DA neurons in the SN and VTA in adult 
mice (Jain, Golden et al. 2006). However, 
the RET cKO mice generated by Kramer 
et al displayed loss of DA neurons in SN, 
nerve terminal degeneration in striatum 
and glial activation starting from one year 
of age. Th ese data  demonstrate that RET 
functions as a critical regulator of long-
term maintenance in the nigrostriatal DA 
system (Kramer, Aron et al. 2007). 
The results of these studies are not 
necessarily contradictory and possibly 
are the result of differences in animal’s 
age at the time of analysis. Further MPTP 
study on cKO RET mutants revealed no 
diff erence in survival of SN DA neurons 
compared to wild type animals. Impaired 
dopaminergic terminal and fi ber regener-
ation, as well as decreased striatal DA con-
centrations appeared during the recovery 
period from toxin damage (Kowsky, Pop-
pelmeyer et al. 2007). Th ey concluded that 
RET does not infl uence the survival of DA 
neurons following MPTP insult, but facil-
itates the regeneration of axon terminals 
(Kowsky, Poppelmeyer et al. 2007). 
Recently the Klein lab found that 
mice lacking DJ-1 and RET in the dopa-
minergic system have a rather signifi cant 
loss of DA neurons in the SNpc, as com-
pared to animals lacking RET in DA sys-
tem (Aron, Klein et al. 2010).
Th e GDNF cKO mice created by Pas-
cual et al. (2008) with suppressed GDNF 
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expression starting from the age of 2 
months, showed progressive decrease of 
brain TH levels and increased cell death 
in locus coruleus, SN and VTA area, with 
progressive hypokinetic symptoms resem-
bling PD pathology (Pascual, Hidalgo-
Figueroa et al. 2008). Authors concluded 
that GDNF has an indispensable role in 
maintenance of the adult DA system (Pas-
cual, Hidalgo-Figueroa et al. 2008). Th ese 
animals exhibited about 60% reduction in 
the GDNF mRNA and protein levels in 
the striatum, but had much more severe 
phenotype than GDNF Hz mice. Th is dis-
crepancy can be explained by the fact that 
deletion of GDNF during embryogenesis 
may lead to compensatory developmen-
tal mechanisms by other factors or by 
non-RET signalling (Pascual, Hidalgo-
Figueroa et al. 2008). The difference in 
results for these conditional GDNF KO 
mice as compared to the results of RET 
conditional KO might be due to the tim-
ing of the deletion, as the RET was deleted 
in cKO animals during embryogenesis as 
compared to two month old mice for the 
GDNF cKO. Another possible explana-
tion for the diff erences between the phe-
notypes of RET and GDNF cKO mice is 
that the increased neuronal death might 
have been triggered by high levels of 
tamoxifen used to induce homologous 
recombination in GDNF cKO mice.
According to a commentary by 
Ibáñez, three possible explanations can 
be appointed for the diff erences. Th e fi rst 
being alternative non-RET mediated sig-
nalling by GDNF, most likely through the 
NCAM receptor. Th e second, most likely 
explanation, is that due to absence of RET 
at embryonic stages, RET independent 
compensatory mechanisms are induced, 
which are normally suppressed by GDNF, 
rendering neurons dependent on GDNF. 
Th is question can be solved by generating 
RET cKO at later developmental stages 
or by selectively inactivating GDNF dur-
ing embryonic development. The third 
option is that RET could, independently 
of GDNF, induce apoptotic dopaminergic 
cell death and GDNF is needed to prevent 
this apoptotic signalling by the receptor 
(Ibáñez 2008).
Studies in our laboratory show that 
diff erent GDNF cKO mice have a mod-
est loss of SNpc DA neurons (Jaan-Olle 
Andressoo - personal communication). 
In addition, RET knock-in mutants 
have been generated where a specifi c tyro-
sine on RET receptor (tyrosine 1062) has 
been replaced by phenylalanine. These 
mice die around P27, are retarded in 
growth and display decreased number of 
enteric neurons, however small kidneys 
develop (Jijiwa, Fukuda et al. 2004). Other 
knock-in models for specific RET iso-
forms have also been generated, but only 
renal and enteric pathologies for these 
defects have been analysed (Jain, Encinas 
et al. 2006).
Th e knock-in  MEN 2B mouse model 
has been generated by introducing a site-
directed mutation, by substitution of the 
threonine in the RET receptor tyrosine 
kinase for methionine at position 918. 
These mice displayed C-cell hyperpla-
sia and chromaffi  n cell hyperplasia pro-
gressing to pheochromocytoma, adrenal 
ganglioneuromas, enlargement of the 
sympathetic ganglia and male reproduc-
tive defect, but lack ganglioneuromas 
of the GI tract (Smith-Hicks, Sizer et al. 
2000). Cancer syndrome does not mani-
fest in these animals before the age of 
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3-4 months, thus they can be utilized in 
studies evaluating the eff ects of constant 
over-activation of the GDNF signalling 
pathway.
1.4.5 GDNF and NRTN in clinical 
studies
Since the possible therapeutic potential 
of GDNF in several neurological disease 
paradigms has been well established in 
preclinical settings, the clinical trials on 
Parkinsonian patients have been under-
taken. However, as GDNF is a relatively 
large protein with molecular weight of 
about 30 kilodaltons, it does not cross the 
blood-brain barrier. The problems with 
protein delivery  to the affected brain 
region have resulted in poor results of 
all clinical trials performed to date. Th e 
fi rst randomized clinical trial conducted 
by Amgen on patients with advanced PD 
concentrated on delivering the protein 
through an intra-cerebroventricular cath-
eter directly to the cerebrospinal fl uid in 
the ventricular space of the brain. How-
ever, no improvement in Parkinsonism 
was seen and several side-effects were 
registered, which lead to the conclusion 
that this route of delivery is ineffective 
since the factor does not reach the target 
tissues (Nutt, Burchiel et al. 2003). It is 
rather surprising that GDNF was deliv-
ered intraventrically, since already at that 
time it was well established that GDNF 
is a basic protein with pI close to 10 and 
with affi  nity to heparan sulfates. 
A trial by Gill et al used direct infu-
sion of GDNF via a catheter and mini-
pump to the posterior putamen of 5 
patients. This open-label trial showed 
remarkably positive improvement in all 
the patients, which persisted for 2 years 
post-treatment (Gill, Patel et al. 2003). 
Very similar results were obtained in a 
study conducted under the direction of 
Dr. D. Gash in Kentucky, where in an 
open-label study 10 patients received 
GDNF unilaterally to striatum for six 
months (Slevin, Gerhardt et al. 2005). Th is 
success lead to the next randomized dou-
ble-blind trial by Amgen, where majority 
of the study approach resembled that of 
Gills study and utilized similar infusion 
of GDNF directly to the brain of 17 PD 
patients, whereas 17 patients received pla-
cebo. Th e conclusions from this trial were 
again negative, as no signifi cant clinical 
effect for GDNF over placebo was seen 
(Lang, Gill et al. 2006). Moreover, anti-
GDNF antibodies developed in 7 patients. 
Th is is very surprising, as brain lacks the 
antibody-generating system. More recent-
ly it has become evident that in fact the 
pump connection in 7 patients was bro-
ken and therefore GDNF had leaked to 
the peripheral tissues of patients. Thus 
only 10 patients out of 17 received GDNF 
intrastriatally and therefore the results of 
this phase II trial were suggested for re-
evaluation (Penn, Dalvi et al. 2006). To 
date these results have not been re-eval-
uated, however several new Phase II trials 
with GDNF are being initiated.
A phase I trial using the adeno-
associated type-2-(AAV2)-NRTN infu-
sion to putamen was performed on 12 
PD patients. Th is trial demonstrated the 
safety of this approach in patients and a 
significant improvement in Parkinso-
nian condition was observed (Marks, 
Ostrem et al. 2008). This was followed 
by a phase II double-blinded trial on 
58 patients (Marks, Bartus et al. 2010). 
After 12 months no statistically sig-
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nificant difference in the conditions of 
patients receiving NRTN gene therapy 
was observed. However, aft er 18 month 
treatment a small, but statistically sig-
nificant benefit of NRTN was observed 
(Ceregene, press release 2010). Conclu-
sions from this study regarding the site 
of administration to the putamen and the 
very modest clinical response led to the 
design of the next phase II clinical trial 
using AAV2-NRTN administration to 
putamen as well as substantia nigra. Th is 
study has been recently launched and is 
currently in the enrolment phase. Unfor-
tunately the plan to deliver NRTN to the 
SN is not well justifi ed. In human mid-
brain NRTN signals to RET via GFRα1 
and not via its cognate receptor GFRα2. 
Th erefore there is a strong risk that NRTN 
signalling, via GFRα1-RET, will similar-
ly to GDNF induce a robust weight loss 
in patients (Manfredsson, Tumer et al. 
2009). Recently published data on animals 
showed that properly scaled and targeted 
AAV2-NRTN to the SN is safe, eff ective 
and causes no weight loss (Bartus, Brown 
et al. 2011).
Th ese trials have led to intensive dis-
cussion on the obstacles related to clinical 
trial design, including diff erences in can-
nula size, concentration of protein, infu-
sion rate and statistical methodology for 
interpretation of the data (Hutchinson, 
Gurney et al. 2007; Matcham, McDermott 
et al. 2007).
Although studies on GDNF as a ther-
apeutic protein in PD clinical trials have 
been halted by Amgen in 2005 and the 
concept of GDNF as a therapeutic mole-
cule was for several years under consider-
ation, scientists have continued to devel-
op diff erent drug delivery approaches to 
encompass the BBB obstacles. Possible 
alternative mechanism include small mol-
ecules which could pass this barrier, gene-
therapy based on viral vectors, implanta-
tion of neural stem cells, implantation of 
growth factor producing cells, increasing 
endogenous GDNF expression in brain 
or receptors functioning as transporters 
of the protein through the BBB (Peterson 
and Nutt 2008; Vastag 2010). 
In conclusion, GDNF and possibly 
also NRTN may have the potential as dis-
ease-modifying therapy for Parkinson´s 
disease. Animal studies on rodents and 
primates have well established the benefi -
cial eff ects on dopaminergic neuron sur-
vival, neuroprotection as well as neurores-
toration, however the clinical use of these 
factors to date has been delayed due to 
diffi  culties in delivery of the factors to the 
aff ected targets in human brain. Impor-
tantly, clinical trials with GDNF and 
NRTN are again under way and hopefully 
will provide promising results for disease 
modifying therapy of Parkinson´s disease.
1.4.6 GDNF role in addic? on
Drug addiction can be viewed as a form of 
behavioural neuronal plasticity. All addic-
tive drugs raise the extracellular levels of 
dopamine in the NAc and caudate/puta-
men. Cocaine increases dopamine lev-
els by blocking the dopamine uptake by 
DAT. Morphine acts on the dopaminer-
gic system through μ-opioid receptors on 
GABAergic interneurons which modulate 
the dopaminergic pathways and induce 
the release of dopamine from basal gan-
glia (Koob and Le Moal 2001). Repeated 
administration of addictive drugs leads 
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to biochemical and morphological altera-
tions, including increased expression of 
TH, glutamate receptors and decreased 
levels of neurofi laments, in the dopamine 
neurons of the VTA and their target neu-
rons in the NAc. 
GDNF has been characterized as one 
of the NTFs having a central role in the 
neuroadaptive processes related to addic-
tion (Carnicella and Ron 2009; Ghitza, 
Zhai et al. 2010). GDNF inhibits the 
rewarding eff ects of drugs by blocking the 
molecular and cellular changes. Infusion 
of GDNF to the VTA results in increased 
TH immunoreactivity in VTA and block-
ing of characteristic biochemical changes 
to drug administration, such as induction 
of protein kinase A subunit and ΔFosB 
transcription factor. GDNF infusion 
also causes behavioural eff ects by reduc-
ing animal`s sensitivity to the rewarding 
effects of cocaine (Messer, Eisch et al. 
2000). Administration of GDNF to VTA 
decreases cocaine and alcohol self-admin-
istration (Green-Sadan, Kinor et al. 2003) 
and reduces place preference. In addition, 
other studies on GDNF using transplan-
tation of GDNF over-expressing cells, 
delivery of nanoparticles with GDNF and 
continuous infusion via mini-pump to the 
striatum led to decreased self-administra-
tion of cocaine in rats (Carnicella and Ron 
2009). Drugs of abuse also decrease the 
endogenous levels of GDNF. Downstream 
GDNF signalling pathways are affected 
as chronic administration of cocaine also 
decreases the levels of phosphorylated Ret 
in the VTA (Messer et al. 2000). It should 
be noted, however that other groups have 
not been able to reproduce these results. 
Conversely intrastiatal infusion of 
GDNF blocking antibody and experi-
ments in GDNF Hz mice showed 
enhanced response, increased sensitiv-
ity to the rewarding effects of cocaine 
and motivation to self-administrate and 
seek metamphetamine (Messer, Eisch et 
al. 2000; Airavaara, Planken et al. 2004; 
Yan, Yamada et al. 2007; Carnicella and 
Ron 2009). It is likely that physiological 
compensatory changes are induced in 
response to drug addiction, reward and 
altered drug-seeking behaviour, such as 
the  increased striatal dopamine levels 
seen in GDNF Hz animals (Airavaara, 
Planken et al. 2004; Airavaara, doctoral 
dissertation 2006; Airavaara, Mijato-
vic et al. 2006; Airavaara, Tuomainen 
et al. 2007).  Th e possible feedback loop 
for GDNF has been described, whereas 
the drugs of abuse decrease endogenous 
GDNF levels and signalling, resulting in 
increased rewarding effects and behav-
ioural sensitivity to subsequent drug 
exposure (Messer, Eisch et al. 2000). It can 
be concluded that chronic drug exposure 
inhibits endogenous activity of GDNF on 
VTA leading to sensitized responses to 
subsequent drug administration (Bolanos 
and Nestler 2004). It has been postulated 
that GDNF and BDNF might have possi-
ble therapeutic potential in treating drug 
addiction (Carnicella and Ron 2009), but 
it is doubtful  that a single neurotrophic 
factors, such as GDNF, could be used in 
treating drug addiction (especially in 
the case of multi-drug addiction), as the 
described eff ects seem to be drug-specifi c, 
brain site-specific and time-dependent 
(Ghitza, Zhai et al. 2010).  
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1.5 VEGF family of growth factors
Vascular endothelial growth factor 
(VEGF) family consists of seven mem-
bers: VEGF-A, -B, - C, - D, - E, - F and 
placental growth factor (PIGF). VEGFs 
signal through receptor tyrosine kinases, 
VEGFR-1,-2 or -3. VEGF-A binds to and 
activates both VEGFR-1 and VEGFR-2, 
VEGF-C and VEGF-D signal through 
VEGFR-2 and VEGFR-3 (Fig.4) (Mäki-
nen, Veikkola et al. 2001; Ferrara, Gerber 
et al. 2003; Tammela, Enholm et al. 2005). 
In addition, VEGFs use as co-receptors 
neuropilin (NRP) 1 and 2, molecules well 
characterized in repulsive axonal guid-
ance processes as receptors for sema-
phorins (Carmeliet and Tessier-Lavigne 
2005). NRP 1 is thought to be essential 
for vascular development, whereas NRP 
2 is considered to be the co-receptor in 
lymphatic development. Functional inter-
action of VEGF-C with neuropilin recep-
tors has been demonstrated (Kärpanen, 
Heckman et al. 2006). Th e direct signal-
ling eff ects of neuropilins in endothelial 
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Figure 4. VEGF family of growth factors and interaction with their receptors. VEGF, VEGF-B, 
PIGF and VEGF-E mediate vasculogenesis and angiogenesis, whereas VEGF-C and –D mediate 
lymphangiogenesis in physiological functioning, as well as during pathogenic processes. Reprint-
ed by permission from  the American Physiological Society  (Physiological Reviews 82, 673-700) 
Copyright © 2002.
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cells are not completely clear, they have 
been thought to play a role in stabiliza-
tion of the VEGFR-2 complex. VEGF 
family is one of the central players in the 
development and maintenance of the vas-
cular system, by inducing vasculogenesis, 
sprouting of blood and lymphatic vessels, 
promoting  proliferation and survival of 
endothelial cells and by increasing vascu-
lar permeability (Tammela, Enholm et al. 
2005). 
VEGF-A is essential during the devel-
opment of the vascular system, by mediat-
ing both vasculogenesis and angiogenesis. 
It induces vascular permeability through 
extravasation of fl uids and protein, which 
in turn activates the migration, prolif-
eration and survival of endothelial cells. 
VEGF-A expression is up-regulated in 
case of injury and hypoxia, but it plays 
also a role in pathological angiogenesis, 
mediating the spread and metastasis of 
cancer cells. In endothelial cells VEGF-
A signalling is mediated through both 
VEGR-1 and -2. At least six isoforms of 
VEGF-A have been described, which are 
generated through alternative splicing 
(Tammela, Enholm et al. 2005). VEGF-
A knockout animals die at E8-9 due to 
defects in vascular formation (Tammela, 
Enholm et al. 2005). 
VEGF-C, the third member of the 
VEGF family, first described by Kari 
Alitalo’s group as a growth factor for 
lymphatic vessels, is 30% homologous 
to VEGF-A (Jussila and Alitalo 2002). 
VEGF-C is mainly expressed around 
developing lymphatic vessels and is rec-
ognized as the key factor in the develop-
ment and regulation of the lymphatic 
system (Jussila and Alitalo 2002). It is 
synthesized as a preproprotein and binds 
to both VEGFR-2 and VEGFR-3. In lym-
phatic system it stimulates the migra-
tion of lymphatic endothelial cells and 
increases vascular permeability through 
VEGFR-3. At higher concentrations it 
also induces blood endothelial cell migra-
tion and angiogenesis through VEGFR-2 
(Jussila and Alitalo 2002). It is up-reg-
ulated in response to proinflammatory 
cytokines, but not hypoxia. During early 
embryogenesis VEGF-C plays a role in 
the development of the blood vascular 
system and later in the generation of the 
lymphatic system. VEGF-C is produced 
as a precursor protein and diff erent forms 
of VEGF-C are generated through proteo-
lytic processing (Tammela, Enholm et al. 
2005). Deletion of VEGF-C in mice leads 
to embryonic lethality, due to the absence 
of lymph nodes, whereas the blood vascu-
lature appears normal (Karkkainen, Hai-
ko et al. 2004).  
  
1.6 Neurovascular crosstalk
The nervous and vascular systems have 
distinct roles in the organism. Th e vessels 
supply and transport oxygen, nutrients 
and solutes to the tissues and the nerves 
are responsible for processing and trans-
mitting information and stimuli. Th e ner-
vous and vascular systems have been con-
sidered to be functionally and structurally 
diff erent units of an organism, however 
lately studies have been published which 
indicate the existence of strong crosstalk 
between these systems and suggest the 
existence of shared growth factors (Car-
meliet 2003; Carmeliet and Tessier-Lavi-
gne 2005; Weinstein 2005; Raab and Plate 
2007; le Noble, Klein et al. 2008). Several 
similarities in the construction of the 
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neuronal and vascular systems do exist. 
It is well established that vessels are oft en 
aligned alongside nerves in the organism. 
Recent evidence has indicated that ner-
vous and vascular systems share common 
organizational principles and that this 
basis for patterning extends to the molec-
ular level, including commonly shared 
growth factors and molecules involved 
in axonal guidance as well as angiogen-
esis. During development sympathetic 
nerves migrate along the vessels to their 
target (Honma, Araki et al. 2002), while 
sensory nerves determine the pattern of 
arterial diff erentiation and vessel branch-
ing (Miller 2002). Thus it is not clear 
whether neurogenesis or angiogenesis is 
the leading process during development. 
Most likely the collaboration between the 
two systems is bi-directional rather than 
unidirectional (Carmeliet 2003; Carmeliet 
and Tessier-Lavigne 2005; Eichmann, Le 
Noble et al. 2005; Weinstein 2005; Laz-
arovici, Marcinkiewicz et al. 2006; Larri-
vee, Freitas et al. 2009). 
The neuro-vascular crosstalk plays 
multiple roles in the development and 
homeostasis of both systems, from target-
derived guidance, migration, patterning 
and remodelling to maintenance and sur-
vival.  Th e deregulation in either of these 
systems, could lead to medically impor-
tant diseases, among them neuropatho-
logical diseases such as Parkinson’s and 
Alzheimer’s disease. Th us understanding 
the mechanisms of neurovascular cross-
talk is the basis to possible future thera-
peutic implications. It should be noted 
that molecular mechanism of neuro-
vascular crosstalk and their implications 
to the pathogenesis of neurodegenerative 
diseases have not been studied extensive-
ly.
Growth factors known to be specifi c 
for the nervous system, have been found 
to have also eff ects on the vascular system, 
as well as factors known to be limited to 
the cardiovascular system have proven 
to be eff ective in neuronal development 
and maintenance (Raab and Plate 2007). 
Th e term „angioneurin“ has been suggest-
ed to define the molecules which affect 
both neural and vascular functioning, 
including eff ects related to regulation of 
angiogenesis, blood-brain barrier integ-
rity, vascular perfusion, neuroprotection, 
neuroregeneration and synaptic plasticity 
(Zacchigna, Lambrechts et al. 2008). Th e 
angioneurins are promising therapeutic 
candidates for the treatment of vascular 
and neuronal diseases. Although tradi-
tionally neurological diseases have been 
considered to result from lesions within 
the neuronal systems, lately the role of 
vascular pathology in disease pathogene-
sis has been described for neurodegenera-
tive diseases such as Alzheimer’s disease, 
Parkinson’s disease, amyotrophic lateral 
sclerosis and dementia, as well as for non-
degenerative pathologies such as stroke 
and epilepsy. Classical neurotrophic fac-
tors - NGF and BDNF can be character-
ized as „angioneurins“, as they have been 
shown to be essential during development 
and formation of the heart and vascula-
ture. They regulate vasculogenesis and 
angiogenesis by autocrine and paracrine 
mechanisms (Zacchigna, Lambrechts et 
al. 2008; Caporali and Emanueli 2009). 
Involved in the crosstalk of the neu-
ronal and vascular systems, is also ARTN 
- a member of the GDNF family. ARTN 
is considered to be a vascular-derived 
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neurotrophic factor for the sympathetic 
neurons, innervating the central and 
peripheral blood vessels (Honma, Araki 
et al. 2002). It remains unclear, whether 
the stimulating effects of neurotrophic 
growth factors on vessel are direct, or 
rather through up-regulation of the level 
of classical angiogenic factors. 
One central player in the crosstalk 
of angiogenesis, neurogenesis and patho-
genesis is VEGF-A which has been well 
characterized as a classical angiogenic 
factor, but recently shown to have multi-
ple roles in the nervous system in normal 
and pathological situations. VEGF-A has 
been shown to have pleiotrophic eff ects 
in the nervous system by enhancing per-
fusion and protection of endothelial cell 
survival, by stimulating endothelial cell 
neurogenic signalling, by promoting the 
survival and protecting from stress sev-
eral types of adult neuronal cells.  VEGF-
A also increases neurogenesis, cognitive 
performance, memory and aff ects synap-
tic transmission, by stimulating neurite 
outgrowth and also by acting on non-
neuronal cells (Zacchigna, Lambrechts 
et al. 2008). Th us in addition to the vas-
culogenic role, VEGF-A has direct eff ects 
on glial and neuronal cells in both central 
and peripheral nervous system. 
Of specifi c interest is VEGF-A role on 
dopaminergic neuronal system. VEGF-A 
has been shown to be neuroprotective in 
both in vitro and in vivo models of Parkin-
son’s disease (Pitzer, Sortwell et al. 2003; 
Yasuhara, Shingo et al. 2004; Yasuhara, 
Shingo et al. 2005; Yasuhara, Shingo et al. 
2005; Tian, Tang et al. 2007).  Th e neuro-
protection is considered to result from a 
direct impact on neuronal survival, as well 
as indirect angiogenic and glial prolifera-
tive eff ects. It is of remarkable interest that 
a neurorestorative eff ect in a rat model of 
Parkinson’s disease has been described for 
VEGF-A (Yasuhara, Shingo et al. 2005). 
VEGF-A immunoreactivity in the SN of 
Parkinsonian patients has been shown 
to be up-regulated whereas no change in 
the expression was seen in the striatum 
(Wada, Arai et al. 2006). VEGF-A levels 
in the serum, however, are not changed in 
PD patients (Infante, Mateo et al. 2007). 
VEGF-A expression by adeno-associated 
virus vector also increases the levels of 
GDNF in the striatum, which by activat-
ing additional RET receptors could result 
in rescuing more DA neurons (Tian, Tang 
et al. 2007). In addition, recent data on 
VEGF-B neurotrophic eff ects have been 
published, where stimulatory effects on 
neurogenesis and protection from moto-
neuron degeneration were demonstrated 
(Sun, Jin et al. 2006; Poesen, Lambrechts 
et al. 2008). In addition, VEGF-B was 
shown to be up-regulated in the rat cell-
culture model of PD and it also exhibit-
ed neuroprotective eff ects in this system 
(Falk, Zhang et al. 2009).
In conclusion, processes that play 
a role in the organism physiology and 
functioning are tightly interacting and 
crosstalk between different systems on 
the molecular and systemic level occurs 
constantly. Th e nervous and vascular sys-
tems converge in multiple pathways, share 
common growth factors and/or receptors 
and represent targets for possible thera-
peutic approaches.  Interpretations of 
therapy response and possible side-eff ects 
should account for this aspect. 
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2. AIMS OF THE STUDY
Th e initial aim of this study was to describe the signalling pathways and target genes 
activated by GDNF in diff erent neuronal systems and experimental conditions includ-
ing in vitro, GDNF KO mouse models, as well as following the over-activation of the 
RET receptor. Th e microarray analysis revealed that GDNF induced the expression of 
the VEGF-C growth factor, which lead to the studies on the neurovascular crosstalk and 
possible neurotrophic role of VEGF-C in the dopaminergic system of rodents, as well as 
during sympathetic development. 
Th e specifi c aims of this study were:
1. To investigate which genes are regulated by GDNF in vitro and in vivo models.
2. To analyse the dopaminergic system of GDNF knockout heterozygous mice.
3. To analyse the eff ects of continuous RET activity in dopaminergic system of 
MEN2B knock-in mice.
4. To develop and validate a medium-throughput computer assisted in vitro dopa-
minergic micro-island assay, in order to facilitate dopaminergic screening of 
growth factors and drug candidates.
5. To study the neurotrophic properties of VEGF-C on the dopaminergic system 
and possible cross-talk with GDNF.
Aims of the Study
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3. MATERIALS AND METHODS
Materials and Methods
Most of the methods used in specifi c studies are described in detail in the original arti-
cles.
Th e following tables list the methods used.
Table 4. List of methodology used in this study.
METHODOLOGY PUBLICATION
Microarray analysis
Microarray hybridization using Aff ymetrix platform IV
RNA and DNA methods
Isolation of RNA and DNA II, III, IV, 
Reverse transcription, cRNA synthesis II, IV, 
Genotyping II, III
Quantitative RT-PCR II, IV
Cell culture methods
In vitro cell culture IV
Primary neuronal cultures III, IV
Immunological methods
GDNF ELISA I
Tissue protein extracts and Western blotting II, IV
Immunohistochemistry IV
Immunofl uorescence cytochemistry III
In silico methods
Primer design IV
Analysis of microarray data IV
Computer assisted quantifi cation III, IV
Statistical analysis I, III, IV
3.1 Microarray analysis
Microarrays allow studying the transcrip-
tion profile of thousands of genes in a 
single experiment. The oligonucleotide 
arrays are one of the most powerful tools 
for genomic research as changes in gene 
expression reflect cellular processes to 
environmental stimuli. Th e transcriptome 
changes, unlike the genomic changes, are 
highly dynamic and rapid. Th e investiga-
tions on expression site and extent allow 
to understand the activity and biological 
role of the transcribed mRNA and respec-
tive protein as well as possible regulatory 
mechanisms, cellular functions and bio-
chemical pathways involved. The tran-
criptome analysis also helps to under-
stand the molecular processes underlying 
disease and to evaluate the possible thera-
peutic applications on cells and organisms 
(Lockhart and Winzeler 2000). 
The Affymetrix GeneChip technol-
ogy utilizes oligonucleotides which have 
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been synthesized on slides by photoli-
thography. Extracted RNA is transcribed 
to cDNA, which is transcribed to bioti-
nylated cRNA. Th e fragmented cRNA is 
hybridized to the microarray slides and 
specifi c staining with biotin-conjugated 
antibodies is measured by a laser scan-
ner. For each gene a set of eleven 25-mer 
oligonucleotide probes are present on the 
array, which provide several independent 
measurements for each transcript and are 
used to measure the level of transcript for 
a gene (Aff ymetrix Inc. www.aff ymetrix.
com).  Each of the 11 probes is paired to 
a mismatch probe containing a mutation, 
this serves as a control for hybridization 
specificity. The Affymetrix probe sets 
represent a series of perfect-match and 
mismatch oligonucleotide pairs, allow-
ing evaluation of non-specific binding, 
normalization of background and perfor-
mance of the probes, providing a robust 
measure of gene expression. Aff ymetrix 
array use feature size of about 8 μm², thus 
the 1.2 cm² slide area contains millions 
of probes. Algorithms evaluate the signal 
from each perfect-match and mismatch 
oligonucleotide probe and provide a sin-
gle signal value for the probe set (Aff yme-
trix Inc.).  
Microarray analysis was performed 
from mouse Neuro 2A-20 cells, treated 
for 48h with 100 ng/ml of GDNF or from 
pooled samples of 12-16 mouse midbrain 
punctures from GDNF Hz and wt ani-
mals. For Neuro2A analysis the cDNA 
synthesis was carried out with Super-
Choice (Invitrogen), biotin labelled cRNA 
was generated from cDNA using IVT 
kit (Enzo, Farmingdale, NY). Fragment-
ed cRNA was hybridized to Affymetrix 
MGU74Av2 chips in triplicate for both 
treatment groups. Chips were scanned 
using the GeneChip Scanner (Affyme-
trix). For GDNF Hz and wt samples One-
Cycle Target Labelling kit (Affymetrix) 
containing the cDNA synthesis kit, IVT 
labelling kit and hybridization controls 
was used. Slides were scanned using the 
GeneChip 3000 scanner (Affymetrix). 
Microarray data was analysed accord-
ing to previously published methodology 
 (Consales, Volpicelli et al. 2007) using 
the robust multiarray average algorithm 
and normalized by the quantile-quantile 
regression method. Additionally data was 
prefi ltered using the Li-and-Wong algo-
rithm and call calculation for each probe 
using the MAS-5 algorithm. Statistical 
analysis was carried out using the SAM 
soft ware (Consales, Volpicelli et al. 2007).
3.2 RNA and DNA methods
RNA was isolated using either the Trizol 
method (Donovan, Lin et al. 2000), 
Ambion RNAqueous Micro kit (IV) or 
Qiagen RNeasy mini kit (unpublished). 
In article II and unpublished microarray 
experiments, cDNA synthesis was per-
formed using TaqMan reverse transcrip-
tion reagents and quantitative RT-PCR 
(qRT-PCR) was performed by SYBR 
green using the ABI Prism 7000 SDS 
system (all by Applied Biosystems).  In 
article IV the cDNA synthesis was done 
with the Transcriptor First Strand cDNA 
synthesis kit (Roche Diagnostics). qRT-
PCR was performed using Lightcycler 480 
SYBR Green system (Roche Diagnostics). 
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3.3 Cell culture methods
Cell culture for validation of microarray 
experiments was performed in vitro from 
Neuro2A-20 cells constitutively express-
ing RET and stably transfected with 
GFR1. Primary cultures were performed 
as described in detail in article III, from 
E13.5 mouse embryo midbrain fl oors or 
P1 SCG neurons. Th e exact growth factor 
concentrations used are listed in respec-
tive publications (III, IV). 
3.4 Immunological methods
GDNF concentrations were measured by 
ELISA methodology, using the GDNF 
Emax immunoassay system (Promega) 
(I). Punctures of striatal tissues or embry-
onic dopaminergic cultures (IV) were 
lyzed using lysis as described in (Rune-
Table 5. List of growth factors used in this study.
Growth factors Source Publications
GDNF PeproTech Ltd., Amgen Inc. III, IV
NRTN PeproTech Ltd. III
VEGF-C Prof. K. Alitalo IV
HB-GAM Prof. H. Rauvala III
berg-Roos, Virtanen et al. 2007). Lysed 
tissue protein extracts were processed for 
Western blotting as described in detail in 
articles II and IV. 
TH immunofluorescence staining 
was performed as described (III, IV). 
RECA-1 immunohistochemistry was per-
formed from free-floating cryosections 
using the reagents from the blood vessel 
staining kit, ECM 590 (Chemicon/Milli-
pore) (IV). 
3.5 In silico methods
Th e primers were designed using either 
ABI Prism Primer Express soft ware (Don-
ovan, Lin et al.2000) or Roche Universal 
ProbeLibrary Assay Design Center (IV). 
The qRT-PCR data was validated using 
qRT-PCR with ABI Prism 7000 soft ware 
(Applied Biosystems) (Donovan, Lin et 
Table 6. List of antibodies used in this study.
Antigen Antibodies Source Publication
TH polyclonal Millipore II
DAT monoclonal Millipore II
TH polyclonal Chemicon III, IV
p-ERK monoclonal Sigma IV
ERK polyclonal Promega IV
RECA-1 monoclonal Monosan IV
c-RET polyclonal Santa Cruz IV
Phosphotyrosine monoclonal Upstate IV
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al. 2000) or Lightcycler 480 soft ware (IV) 
followed by analysis with the comparative 
threshold cycle (CT) method 2-ΔΔCT (II, 
IV). Microarray raw data were initially 
analysed using MAS 5.0 soft ware followed 
by data mining using Genespring soft ware 
(Agilent Technologies/ Silicon Genetics). 
Statistical analysis of data is described in 
respective articles.
DA neuronal survival in culture was 
analysed by taking a picture of the whole 
micro-island area using a fluorescence 
stereo-microscope (Leica MZ FL III), 
at 3.2 x magnifi cation with the GFP fi l-
ter. Background normalization was per-
formed in Adobe Photoshop software 
version 6.0.1, followed by quantifi cation 
of cell number in Image Pro 5.1 soft ware 
(Media Cybernetics) (III).  
RET phosphorylation and pERK 
activation data were measured in AIDA 
Image Analyzer soft ware (Raytest). Den-
sitometry quantifi cation was performed 
using the histogram profi les which were 
measured for all bands (IV).
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4. RESULTS AND DISCUSSION
4.1 GDNF induced genes in cell 
culture
Microarray analysis of Neuro2A-20 cells 
treated with 100 ng/ml of GDNF for 48h 
was performed using Aff ymetrix mouse 
genome U74Av2 chips in three replicates 
for each group. Data analysis revealed 
gene expression changes over 1.6 fold for 
39 genes, of which 25 were up-regulated 
and 14 down-regulated following GDNF 
treatment. Of these, 18 diff erentially regu-
lated genes were selected for confi rmation 
using qRT-PCR from independent experi-
ments (Fig.5). The correlation between 
microarray data with qRT-PCR results 
was 94% with only one gene remain-
ing unchanged according to qRT-PCR 
measurement. Th us the GDNF regulated 
genes detected by microarray analyses 
showed similar regulation as measured by 
qRT-PCR, although the exact level of fold-
change varied slightly between the two 
techniques. In regard to functional char-
acterization of GDNF-induced genes, two 
distinctive processes can be distinguished 
among the up-regulated genes: the immu-
nological and vascular processes. The 
genes of the immune system  up-regulated 
by GDNF treatment include: interleukin 6 
(IL-6) – the top most up-regulated gene, 
prostaglandin-endoperoxide synthase 1 
(COX1), VEGF-C, endothelial protein C 
receptor, annexin A2, cytotoxic T lym-
phocyte-associated protein 2ɑ , sphin-
gosine-1-phosphate-phosphatase, T-cell 
death associated gene, cytotoxic T lym-
phocyte-associated protein 2β, S100 calci-
um binding protein A10 (calpactin), cyto-
kine inducible SH2-containing protein, 
prostaglandin I receptor and urokinase 
plasminogen activator receptor. Genes of 
vascular processes up-regulated by GDNF 
included: VEGF-C, endothelial protein C 
receptor, annexin 2, tissue plasminogen 
activator, FGF-regulated protein, calpac-
tin and urokinase plasminogen activator 
receptor.
Classically the immune system has 
been considered to function indepen-
dently from the nervous system and the 
immunological processes have not been 
associated with normal brain functioning, 
rather characterized as part of pathogenic 
mechanisms activated in the brain follow-
ing BBB disruption during pathological 
conditions in the CNS. Th ere is growing 
evidence on the role of immunogenic pro-
teins in normal functioning of the ner-
vous system including stem cell renewal, 
cell fate decisions, neuronal diff erentia-
tion and synaptic plasticity (McAllister 
and van de Water 2009). Molecular cross-
talk between the immune and nervous 
systems has been demonstrated, includ-
ing secretion of several overlapping fac-
tors, which are not restricted to either 
system. The factors displaying pleiotro-
phic roles in the immune and nervous 
system include NTFs (NGF, GDNF fam-
ily ligands, neuropoietic cytokines – IL-6, 
CNTF, LIF), cytokines and chemokines 
(Kerschensteiner, Meinl et al. 2009). Th e 
cytokines have been regarded to func-
tion in two distinct ways as: a) proinfl am-
matory cytokines - which aggravate the 
pathogenic processes acting destructively 
on neuronal pathways and b) anti-infl am-
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matory cytokines – which act neuropro-
tectively. However, this distinction might 
not hold true, as depending on the timing 
and context the same cytokines have been 
shown to exhibit either neuroprotective 
or neurodestructive eff ects. Th e infl am-
matory process in the CNS, in addition 
to the well-known neurotoxic eff ect, can 
also result in neuroprotection. The bal-
ance between protective and destruc-
tive factors is regarded to be the basis of 
neural-immune functioning and provides 
the outlook for possible future therapeutic 
implications (Kerschensteiner, Meinl et al. 
2009; McAllister and van de Water 2009). 
In addition, there seems to be functional 
resemblance between the immune and 
neuronal system, as the immunological 
synapses, similarly to neuronal synapses, 
are asymmetric structures between two 
cells that secrete molecules to the eff ector 
cells and interestingly they share the same 
proteins and adhesion molecules that 
regulate specifi city of synapse formation, 
cytoplasmic signalling and interactions 
(Yamada and Nelson 2007; McAllister and 
van de Water 2009). 
We could further classify the genes 
up-regulated by GDNF in our study 
to be related to the vascular processes. 
Th ese genes included: VEGF-C, endothe-
lial protein C receptor, annexin 2, tissue 
plasminogen activator, FGF-regulated 
protein, calpactin and urokinase plas-
minogen activator receptor. Since no data 
existed on the eff ects of VEGF-C in the 
nervous system and very little was known 
about the regulation of the innervation of 
lymphatic vessels, we focused on VEGF-C 
and its possible link to the nervous sys-
tem, which provided the basis for further 
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Figure 5. GDNF induced genes in Neuro2A cells. Comparison of the fold-change levels of 16 
genes most regulated by GDNF, as measured by microarray and qRT-PCR analysis. 
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studies which are discussed later in the 
results section. 
A similar experimental setup was 
performed using treatment of Neu-
ro2A-20 cells with 100 ng/ml of NRTN, 
however this experiment did not result in 
any signifi cant gene expression changes 
above 1.5 fold.
4.2 GDNF induced genes in 
animal models
In order to further characterize GDNF 
signalling using samples from in vivo 
GDNF models, we performed microar-
ray analysis from pooled SN/VTA sam-
ples, isolated from adult GDNF Hz and 
wt mouse brains. Th e Aff ymetrix mouse 
genome 430 2.0 microarrays, with 39 000 
transcripts, were tested with three pooled 
samples (n=7-8 per pool) for both the 
GDNF wt and Hz group. When setting the 
fold change cut-off  at 1.5 we found very 
few signifi cantly changed genes. In order 
to test the diff erences between our sam-
ples, we performed correlation analysis 
on the results obtained from the microar-
rays and found that two of the wt samples 
grouped together with the Hz samples 
and one wt sample differed remarkably 
from the other wt samples. We conclud-
ed, that the dissection and pooling of 
midbrain samples had been problematic 
in our experimental setup, which could 
have masked the real diff erences in gene 
expression and diluted the measurable 
eff ects of GDNF deletion in these animals. 
Despite these issues it was of interest for 
us to compare the gene expression levels 
of the least similar of the wt experiment to 
the mean of expression levels of the three 
Hz chips, in order to see if we could fi nd 
any GDNF associated genes of scientifi c 
interest. Th is analysis resulted in 583 dif-
ferentially regulated genes, with 358 up-
regulated and 225 down-regulated genes. 
Th e results of this analysis were further 
classifi ed into functional groups using the 
Gene Ontology (GO) classifi cation (Table 
7). 
We found a long list of highly rel-
evant changes, including genes related 
to signalling, apoptosis, dopaminergic 
and glutamatergic system, ion channel 
related genes, vesicular traffi  cking genes 
as well as growth factors. Remarkable was 
the fact that when comparing the result-
ing gene lists of the GDNF Hz animals to 
the Neuro 2A-20 results, we found none 
of the genes overlapping between the two 
experiments. On the other hand GDNF 
treatment and lack of GDNF are rather 
different experimental conditions, still 
one would expect at least some overlap 
between the results. 
In addition, we studied the gene 
expression lists created by other groups 
who had been studying GDNF-induced 
gene expression by microarray analy-
sis. Four diff erent microarray studies on 
GDNF-induced gene expression have 
been published. Two studies have been 
performed on spermatogonial stem 
cells (Braydich-Stolle, Nolan et al. 2005; 
Schmidt, Avarbock et al. 2009). One 
study has been performed on embryon-
ic rat midbrain dopaminergic cultures, 
using acute stimulation and treatment 
with 10 ng/ml of GDNF for 3h, utilizing 
the Aff ymetrix platform (Consales, Vol-
picelli et al. 2007). Th e fourth study was 
performed on embryonic and postnatal 
intact dorsal root ganglion neurons treat-
ed with 20 ng/ml of GDNF for 2h, with 
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Table 7. Functional classifi cation of GDNF induced genes in GDNF Hz midbrain samples. 
DOWNREGULATED GENES FC UPREGULATED GENES FC
GROWTH FACTORS/RECEPTORS
brain-derived neurotrophic factor
decorin
kit oncogene (stem cell factor receptor)
insulin-like growth factor I receptor
insulin-like growth factor II
neuregulin I (glial GF 2)
2.1
1.6
1.6
1.5
1.5
1.5
GROWTH FACTORS / RECEPTORS
ret proto/oncogene 
growth hormone
neurotrophic growth inhibitory factor 
(metallothionein 3)
1.9
2.7
1.7
SIGNALLING
sprouty homolog 2
sprouty homolog 4
phosphatase and tensin homolog
SOCS2
protein phosphatase 3 - calcineurin A
protein phosphatase 3
protein phosphatase 1 – myosin phosphatase
ubiquitin protein ligase E3A
ubiquitin-conjugating enzyme E2D 2
similar to ubiquitin specifi c protease 1
ubiquitin carboxyl-terminal esterase L5
proteasome 16S subunit 12
phosphatidylinositol glycan, class F
phosphatidylinositol 3-kinase, α polypeptide
phosphatidylinositol 3-kinase, polypeptide 1
pleckstrin homology domain-containing 
family A member 3
inositol triphosphate receptor type 2 gene
inositol (myo)-1(or4)-monophosphotase 1
inositol 1,4,5-triphosphate receptor 1
neurogranin (PK C substrate)
cAMP-dependent proteiin kinase inhibiitor
regulator of G-protein signalling 16
serine/threonine kinase 18
KH domain containing, signal transduction 
associated 3
RAB 10
3.3
1.8
2.1
1.6
2.2
1.5
1.7
1.6
1.8
1.8
1.5
1.7
2.9
2.9
1.6
1.6
1.7
1.6
2.0
1.9
1.7
1.7
1.5
1.5
1.6
SIGNALLING
guanine nucleotide binding protein, β2, 
related seq
Rap1, GTPase-activating protein 1
regulator of G-protein signalling 10
protein kinase, cAMP dependent, 
catalytic α
protein kinase, cAMP dependent 
regulatory, type Iβ
protein tyrosine phosphatase, receptor 
type S
phosphatidylinositol glycan, class Q
MAPK 8 interacting protein 3
protease, serine, 18  
serine/threonine kinase 39, STE20/SPS 
1 homolog
1.9
1.6
1.6
1.6
1.6
1.6
1.6
1.5
2.2
1.7
GLUTAMATE SYSTEM
GABA-A transporter 1 
AMPA receptor subunit /GluR-B) gene, 2 
alternative transcript
glutamate receptor, ionotropic, AMPA3 (α3)
vesicular glutamate transporte, member 6
NMDA receptor-regulated gene 1
1.9
2.0
1.6
2.0
1.5
DOPAMINE AND GLUTAMATE 
SYSTEM
engrailed 1
dopamine receptor 2
tyrosine hydroxylase
dopamine transporter
DA and cAMP regulated phosphoprotein 
(DARP32)
glutamate dehydrogenase
GABA/B receptor 1
glial fi brillary acidic protein
2.4
2.3
1.8
1.6
1.5
1.5
1.5
2.2
39
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ION RELATED
solute carrier family 4, sodium bicarbonate 
cotransporter like 10
solute carrier family 4 (anion exchanger), 
member 4
solute carrier family 31 (copper transporter), 
member 1
solute carrier family 24 (Na/K/Ca exchanger), 
member 3
ryanodine receptor 3 (i/c Ca store releaser)
ATPase, H+ transporting lysosomal (vacuolar 
proton pump)
K inwardly-rectifying channel. subfamily J, 
member 9
voltage-dependent anion channel 2
2.1
1.8
1.5
1.5
1.8
1.6
1.5
1.5
ION RELATED
voltage/dependent Na+ channel β1 
subunit gene
supressor of K+ transport defekt 3
hyperpolarization activated cyclic 
nucleotide gated K+
plasmolipin
Ca channel, voltage dependent, 
γsubunit 4
Cu/Zn superoxide dismutase
Ferritin heavy chain
erritin L/subunit gene exons 1-4
EST, highly similar to transferrin
lipocalin 2
2.1
1.8
1.8
1.9
1.8
1.6
1.6
1.5
1.9
1.8
APOPTOSIS
caspase 8 associated protein 2
Bcl2-associated athanogene 3
Bcl2-interacting killer-like
cytochrome c oxidase, subunit XVII assembly 
proteiin homolog
2.0
1.9
1.6
1.5
VESICULAR TRANSPORT
secretory carrier membrane protein 2 - 
SCAMP 2
secretory carrier membrane protein 5 - 
SCAMP 5
1.9
1.6
Table 7. cont. 
the Affymetrix platform (Linnarsson, 
Mikaels et al. 2001). Quite surprisingly 
comparison of differentially regulated 
gene lists did not reveal any common 
pathways or genes between these and 
our studies. Th e above described diff er-
ent microarray analysis raised a number 
of questions: Why were there so few dif-
ferentially regulated genes? Why were the 
gene expression fold change levels so low? 
Why were there so few common genes 
between diff erent experimental setups of 
GDNF functioning? 
Of possible explanations to the lack 
of common changes in gene expression, 
could be that all the experiments were 
conducted on diff erent cell lines or neu-
ronal systems, the used concentrations of 
GDNF protein varied and also the treat-
ment times used were diff erent. For exam-
ple in our Neuro2A-20 cell culture experi-
ment we used a 48 h time-point for GDNF 
treatment, expecting the results to reveal 
changes in genes which are involved in 
GDNF mediated cellular diff erentiation 
processes. Shorter treatment times would 
have most probably pinpointed immedi-
ate early genes and transcription factors 
associated with GDNF-related processes.
Th e above raised questions could also 
be explained by the highly complex nature 
of the nervous system. One issue is the 
heterogeneity of neuronal samples – cell 
culture samples and brain tissues contain 
a pheno- and genotypically diverse popu-
lations of cells, thus the gene expression 
changes in a specific subpopulations of 
cells might be masked by expression sig-
nals from accompanying cells. Th e hetero-
geneity causes a signal-to-noise problem 
in the detection of gene expression chang-
es from a specifi c cell type (Henry, Zito 
et al. 2003; Mirnics and Pevsner 2004). 
Th is could be one reason for the lack of 
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overlap between our diff erent experimen-
tal results. One possible solution to this 
aspect might be achieved by the single 
cell laser capture technique, where the 
specifi cally stained cells are laser capture 
punctured from surrounding tissue and 
the RNA is amplifi ed and gene expression 
analysis performed on this preselected 
homogenous subgroup of cells. Another 
issue is that in mature nervous system 
de novo gene expression induction and 
repression is rarely seen, thus the chang-
es are too small to be detected above the 
background noise (Henry, Zito et al. 2003; 
Mirnics and Pevsner 2004). This could 
explain the low levels of fold changes in 
our experiments. Another aspect is that 
neurons project to remote areas, thus the 
site of sampling is of critical importance. 
Although the changes in gene expres-
sion might take place in the cell body, the 
results of this change might be refl ected 
in the eff ector regions (Henry, Zito et al. 
2003; Mirnics and Pevsner 2004). Rel-
evant to the GDNF Hz  studies might also 
be the endogenous compensatory chang-
es which have taken place following the 
40-50% reduction in GDNF levels (Pas-
cual, Hidalgo-Figueroa et al. 2008), thus 
the true changes regarding the GDNF 
eff ect might not have been refl ected in our 
analysis. 
In conclusion, changes in GDNF-
induced gene expression seem to be high-
ly dependent on the experimental setup 
including the concentration of the factor 
used, the type of cells under study and the 
duration of treatment. In addition, com-
pensatory changes from the surrounding 
environment can mask the specifi c signal 
from certain cell types, as the magnitude 
of change in gene expression levels of neu-
ronal systems does not seem to be very 
high. Our microarray gene expression 
analysis suggests that GDNF intervention 
could induce crosstalk on the molecular 
level between diff erent physiological sys-
tems, including vascular and infl amma-
tory systems.
4.3 Dopaminergic system of 
GDNF heterozygous mutant 
mice
We further studied the eff ects of deple-
tion of one allele of GDNF gene on the 
dopaminergic system. Initially the GDNF 
levels were measured in ventral and dor-
sal striatums of GDNF Hz and wt animals 
using protein measurement by ELISA. 
Th e results showed a signifi cant reduction 
by 44% (p-value-0.009) in the GDNF pro-
tein level in the dorsal striatum of GDNF 
Hz mice as compared to wt littermates. 
An 18% reduction was also present in 
ventral striatum, however this change was 
not signifi cant (p-value-0.085). 
Th e brain dopamine concentrations 
can be measured in two different ways. 
Th e fi rst being measurement of post-mor-
tem striatal tissue concentration using 
high-performance liquid chromatography 
(HPLC) with electrochemical detection. 
Th is method is used to study the chem-
istry of a tissue on the intracellular level. 
Th e other option is to measure the in vivo 
extracellular concentration of a molecule 
using microdialysis. Using this method 
the concentrations can be measured over 
an extended period of time in living and 
moving animals. As the post-mortem tis-
sue concentrations of dopamine in GDNF 
Hz animals have been shown to be unal-
tered (Gerlai, McNamara et al. 2001) we 
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decided to monitor the in vivo extracel-
lular dopamine levels using the microdi-
alysis method. Th ese studies revealed that 
the extracellular dialysate concentrations 
were signifi cantly elevated in the GDNF 
Hz mice compared to wt by 2-fold in CPu 
and by 1.6-fold in the NAc. The dopa-
mine metabolites DOPAC and homova-
nillic acid (HVA) showed no signifi cant 
increase in GDNF Hz animals. 
FosB/ΔfosB levels have been shown 
to be increased following repeated use of 
drug of abuse (Nestler 2005). In order to 
study the postsynaptic activity in GDNF 
Hz animals FosB immunoreactivity 
was measured by immunostaining. An 
increase in the level of FosB/ΔfosB nuclei 
was 5.7 fold in CPu and 2.2 in NAc core 
and 1.6 fold in NAc shell of the GDNF 
Hz mice compared to wt. Th is elevation 
could be linked to the increased extracel-
lular dopamine levels in these regions and 
indicate sustained postsynaptic activation 
of these areas. No signifi cant change was 
seen in behavioural experiments in basal 
locomotor activity. 
Th e fi nding that extracellular dopa-
mine levels are increased by two fold 
in GDNF Hz animals, who exhibit 44% 
reduction in GDNF levels, is unexpected. 
It is unlikely that the increased extracel-
lular DA levels are the result of changes in 
dopamine synthesis, storage or metabo-
lism as these changes should also have 
an effect on total tissue levels of DA, 
which remain unchanged in GDNF Hz 
animals (Gerlai, McNamara et al. 2001). 
In addition, the elevated extracellular 
DA  unlikely results from increased DA 
cell number in SN, as the number and 
density of SN dopamine cells and stria-
tal innervations have been shown to be 
unchanged in GDNF knockout and het-
erozygous embryos (Moore, Klein et al. 
1996; Pichel, Shen et al. 1996; Sanchez, 
Silos-Santiago et al. 1996). Several mecha-
nisms can be considered as the underly-
ing cause for this increase in GDNF Hz 
animals. The most likely explanation is 
that elevation of extracellular DA could 
be a compensatory change, in order to 
enhance the synthesis of endogenous 
GDNF. Regulation of GDNF synthesis by 
dopamine through D1-receptor has been 
demonstrated (Ohta, Mizuta et al. 2000; 
Ohta, Kuno et al. 2003). Another possible 
explanation is that synapse formation in 
the GDNF Hz animals could be decreased 
and that increase in dopaminergic output 
is a compensatory eff ect for normal neu-
ronal functioning. GDNF is considered to 
induce axon outgrowth, synapse forma-
tion and efficacy of dopaminergic neu-
rons and it is likely that axon branching 
and synapse formation differ in GDNF 
Hz animals as compared to wt (Bourque 
and Trudeau 2000; Granholm, Reyland et 
al. 2000; Airaksinen and Saarma 2002). In 
conclusion, the results of elevated dopa-
mine levels in striatal and limbic brain 
areas in animals with decreased levels of 
GDNF, indicate activation of neuronal 
networks and the importance of GDNF 
signalling in the dopaminergic system. 
4.4 Dopaminergic system of 
MEN2B knock-in mice
In order to further study the RET sig-
nalling in vivo, the dopaminergic sys-
tem of the adult MEN2B (M/M) animals 
was investigated. In these animals the 
Met919Thr mutation has been intro-
duced, leading to continuous activation of 
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RET tyrosine kinase. Th ese animals thus 
represent a model corresponding to the 
permanent activation of Ret by GFLs. Th e 
homozygous M/M animals develop C cell 
hyperplasia by the age of 6-10 months, 
but pheochromocytoma does not develop 
before 3 months of age. We used the ani-
mals at the age of 10-12 weeks, to avoid 
infl uence of the pathological abnormali-
ties in the investigation of the dopaminer-
gic system. 
Initially the monoamine – dopamine, 
noradrenaline and serotonin – extra-
cellular concentrations in wt, M/+ and 
M/M animals were measured by HPLC 
with electrochemical detection. A robust 
increase of 100% in DA levels in striatum 
of M/M homozygous mice was discov-
ered, whereas the heterozygous M/+ ani-
mals showed about half increase (47%) as 
compared to wt animals. A similar sig-
nifi cant increase in striatal DA metabolite 
levels was measured in  M/M and M/+, 
as compared to wt animals: 148% and 
108% for DOPAC  and HVA respectively 
in M/M animals and 50% and 30% for 
DOPAC and HVA in M/+ animals. Th e 
cortical measurements showed increased 
DA levels of about 70% in both homozy-
gous and heterozygous animals, whereas 
in the hypothalamus about 30% increase 
in DA levels was present only in M/M ani-
mals. No signifi cant changes were detect-
ed in serotonin levels in any brain region 
and a 27% change in noradrenaline levels 
was visible only in the lower brainstem of 
M/M animals. 
To understand the possible mecha-
nisms of elevated DA levels, we further 
investigated the dopaminergic system 
of MEN2B animals on the protein level. 
Immunohistochemistry was performed 
on free-floating striatal sections from 
M/M, M/+ and wt animals. Th e striatal 
TH-protein optical density measurements 
showed  increased levels of TH by about 
75% in M/M and by 55% in the M/+ 
genotype, as compared to wt. Dopamine 
transporter (DAT) staining was increased 
similarly by about 50% in striatal sections 
for both M/+ and M/M genotypes as com-
pared to wt.  Further Western blotting for 
both TH and DAT levels was performed 
from striatal and SN/VTA punctures from 
all three genotypes. M/+ and M/M ani-
mals had a gene dose-dependent increase 
in TH protein levels in both striatal and 
SN/VTA samples. An increase was also 
visualized for DAT levels in striatal sam-
ples for both genotypes as compared to 
wt. Quantifi cation of TH protein expres-
sion levels in SN/VTA Western blotting 
showed a 180% increase for M/M ani-
mals and 60% increase for M/+ animals as 
compared to wt. 
Gene expression levels for Th and 
Dat were measured using quantitative 
RT-PCR from SN/VTA samples of the 
M/M and wt genotypes (Fig.6). A statis-
tically signifi cant increase of 2.5 fold in 
Th  mRNA expression levels was detected 
for M/M  animals as compared to wt. 
Although Dat mRNA expression change 
of 2.7 fold was also detected for M/M 
animals, no statistical significance was 
reached. The expression levels of other 
genes were studied in samples from M/M 
and wt SN/VTA, including Gdnf, Gfrα1, 
Dopa decarboxylase and dopamine D1 
receptor, however no change in expression 
was seen. Also the Gdnf mRNA expres-
sion levels were unchanged in striatum of 
MEN2B/MEN2B animals as compared to 
wt littermates. 
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Th e increase in DAT and TH mRNA 
and protein levels of MEN2B animals 
is in line with other studies, which have 
shown that exogenously administered 
GDNF leads to higher DA levels and DA 
turnover in vivo, as well as increases Th  
mRNA expression and stability in vitro 
(Hudson, Granholm et al. 1995; Mar-
tin, Miller et al. 1996; Gash, Zhang et al. 
2005). Also GDNF has been shown to 
enhance the phosphorylation of TH in the 
striatum and SN of rats (Salvatore, Zhang 
et al. 2004). However, studies of chronic 
treatment of adult rats with GDNF have 
shown no changes in DA concentrations 
and rather decreased tyrosine hydroxylase 
mRNA and protein expression (Rosen-
blad, Georgievska et al. 2003; Georgievs-
ka, Kirik et al. 2004). Th e possible expla-
nation for this discrepancy could be that 
in the above cases very high level of exog-
enous GDNF was expressed in the mature 
adult dopaminergic system and compen-
satory mechanisms can be activated to 
maintain the normal neuronal function-
ing, whereas in the MEN2B animals the 
continuous Ret signalling is permanent 
from early developmental stages. 
Next, we hypothesized that the above 
described changes were due to increased 
DA cell number in the SN and VTA. TH 
immunochemical staining followed by 
stereological analysis was performed on 
dopaminergic neurons of SNpc and VTA. 
A statistically signifi cant (26%) increase 
in TH-positive cell number was visual-
ized in homozygous M/M animals in 
SNpc cells as compared to wt animals, 
but no statistically significant elevation 
in dopamine cell number was seen in 
heterozygous M/+ animals. No differ-
ences in TH-positive cell numbers for the 
three genotypes was found in VTA dopa-
minergic neurons, thus the RET-depen-
dent increase in dopamine cell number 
seems to be confined to the nigral DA 
neurons. Further, we decided to inves-
tigate striatal DAT-positive varicosities 
for sprouting of dopaminergic neurons. 
However, although we could visualize an 
increase of 20% in the number of DAT-
positive terminals in homozygous M/M 
animals as compared to wt, no increase 
was seen in heterozygous M/+ animals. 
Further behavioural experiments assess-
ing locomotor activity were performed 
on MEN2B animals. Spontaneous loco-
motor activity in nonhabituated animals 
declined in all three genotypes during the 
60 minutes, however, both M/M and M/+ 
animals showed similar decreased loco-
motor activity levels as compared to wt. 
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 Figure 6. qRT PCR from wt and 
M/M animals for Th and Dat 
mRNA. Changes in gene expression 
levels for Th  and Dat in M/M ani-
mals were measured as fold change 
of wt samples. Th e fold change level 
for Th  was up-regulated by 2.5 fold 
(p=0.04) and for Dat by 2.7 fold 
(p=0.067). n=5-6 in each group. * 
p<0.05 students t-test. 
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Interestingly, no diff erences in the three 
genotypes appeared in habituated animals 
during 24 hours. 
Thus our study on the dopaminer-
gic system of MEN2B animals revealed a 
robust increase in DA and metabolite lev-
els in the mesolimbic, mesocortical and 
nigrostriatal systems of these animals. 
Th is eff ect seems to be specifi c and con-
fi ned to the dopaminergic system, as no 
signifi cant elevation in serotonin or nor-
adrenaline levels was seen in the MEN2B 
mice. Th e increased levels of DA can be 
partly explained by increased nigral dopa-
minergic cell numbers, however this was 
evident only in the homozygous animals. 
Th us it is likely that the above mentioned 
changes are mostly due to increased dopa-
mine synthesis, which is further support-
ed by increased TH mRNA and protein 
levels. GDNF and RET signalling is not 
considered to be important for prenatal 
development of nigral dopaminergic neu-
rons (Marcos and Pachnis 1996; Moore, 
Klein et al. 1996; Pichel, Shen et al. 1996; 
Sanchez, Silos-Santiago et al. 1996; Eno-
moto, Araki et al. 1998), but rather to 
function during early stages of postnatal 
apoptotic cell death (Burke, Antonelli 
et al. 1998; Oo, Kholodilov et al. 2003; 
Kholodilov, Yarygina et al. 2004). Thus 
the increased number of dopaminergic 
neurons in MEN2B animals could result 
from rescuing of dopaminergic neurons 
and suppression of apoptosis by continu-
ous activation of RET. Another possibil-
ity is that overexpression of RET during 
embryonic development causes develop-
ing neurons to acquire the dopaminergic 
phenotype. 
Mijatovic et al. have further studied 
the mechanisms of increased DA lev-
els in MEN2B animals and found this to 
result from enhanced synthesis of DA 
leading to increased storage and release 
from pre-synaptic terminal pools. Also 
higher re-uptake of DA has been shown 
in these animals, leading to unchanged 
basal extracellular DA levels (Mijatovic, 
Patrikainen et al. 2008; Mijatovic 2009). 
In addition, neurotoxin PD model studies 
have been performed in MEN2B animals. 
Th e unilateral 6-OHDA injection to stria-
tum showed significant resistance and 
lower TH-positive nigral neuronal loss 
in the MEN2B mice. Th e response to sys-
temic MPTP was unaltered in the MEN2B 
animals as compared to wt, however this 
could have been due to utilization of the 
„milder“ toxin model (Mijatovic, Piltonen 
et al. 2011). This study concluded that 
RET signalling is important for GDNF-
induced neuroprotection of DA cell bod-
ies but not for striatal dopaminergic nerve 
terminals (Mijatovic 2009; Mijatovic, Pil-
tonen et al. 2011). 
4.5 A new method to assay the 
survival of dopaminergic 
neurons  in vitro
In order to initially assess the dopamino-
trophic properties of a protein, factor or 
a chemical compound, quantifi cation of 
the survival of rodent midbrain neurons 
in culture is oft en performed. However, 
all current techniques are limited due to 
the scarcity of material, assay unreliability 
and variability, low throughput and sta-
tistical power, arduous workfl ow, human 
error in quantifi cation as well as diffi  cul-
ties in applications to KO studies. We 
have further enhanced the micro-island 
culturing technique, initially described by 
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Takeshima et al. (Takeshima, Shimoda et 
al. 1996), by creating a standardized tem-
plate to form micro-islands of a defi ned 
size, followed by computer based quanti-
fi cation of cell survival using two diff er-
ent parameters – TH intensity level and 
TH-positive cell number. Th is method has 
been validated by quantifi cation of sur-
vival of GDNF treated cultures, resulting 
in highly signifi cant survival rate in the 
treatment group with p-value up to 10-10. 
The quality of stained cultures 
enables the capture of high magnifi cation 
images for quantifi cation of neurite out-
growth, as demonstrated in publication 
III. Th e sensitivity of the method allows 
studies on additive eff ects of diff erent fac-
tors, as demonstrated by co-treatment 
with GDNF/NRTN and GDNF/HB-
GAM. Another benefit of the method 
is the possibility to culture embryonic 
midbrains from single KO or transgenic 
animals where the genotype is unknown 
at the time of isolation, resulting in 10 
cultures per genotype. This has been 
impossible previously due to the limited 
amounts of sample material. We demon-
strate the applicability of this method on 
RET KO animals, where surprisingly we 
observed an increase in TH levels but not 
in TH-positive cell number in the RET 
KO group. This indicates to-non-RET 
signalling, which affects TH expression 
levels but does not aff ect the number of 
surviving dopamine cells. Although the 
unchanged cell survival rate in RET KO 
has been demonstrated previously (Tara-
viras, Marcos-Gutierrez et al. 1999), the 
increase in TH levels in non-RET signal-
ling has not been described and warrants 
further studies. 
In addition, the method is appli-
cable on parallel functional studies of 
DA metabolism as demonstrated by DA 
uptake measurements followed by GDNF 
treatment. Finally, the method is applica-
ble on other neuronal tissue cultures with 
limited amounts of material, as demon-
strated by performing micro-island cul-
tures from post natal day 1 SCG neurons.
Th is enhanced micro-island culture 
method with computer assisted image 
analysis aids in sensitive evaluation of 
the dopaminotrophic properties of pro-
teins, chemical compounds or their com-
binations. Additionally, data from single 
embryos can be analysed and parallel 
functional studies performed. In case of 
automation, the method can be utilized 
for small scale screens of chemical librar-
ies on primary dopaminergic neurons.
4.6 Neurotrophic eﬀ ects of 
VEGF-C in the dopaminergic 
system 
In order to study the neurotrophic eff ects 
of VEGF-C on the dopaminergic system, 
in vitro embryonic mesencephalic mid-
brain cultures from E13.5 mice were pre-
pared. Th e cultures were plated using the 
above described micro-island method and 
treated with 100 ng/ml of VEGF-C, 10 ng/
ml of GDNF or both factors simultane-
ously for 5 days. Quantification of TH-
positive neurons revealed a significant 
increase of 13% in the VEGF-C treated 
and up to 40% increase in the GDNF 
treated wells, as compared to control buf-
fer treatment (Fig.7). Th us VEGF-C eff ect 
on embryonic dopamine neurons seems 
to be about half of the effect of GDNF. 
However, no further additive eff ects were 
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Figure 7. VEGF-C effect on the sur-
vival of dopamine neurons in culture 
in vitro. Quantifi cation of TH positive 
neuronal survival as percentage from 
untreated control samples. VEGF-C 
100 ng/ml induced survival of 13% as 
compared to untreated samples. GDNF 
10 ng/ml induced 40% more survival 
as compared to control. Simultaneous 
addition of 100 ng/ml of both VEGF-
C and 10 ng/ml GDNF did not result 
in further signifi cant neuronal survival as compared to GDNF alone (p=0.6). Means ±SEM are 
shown; n=32-68 in each group.   * p<0.01 , * * * p<0.0001 treatment versus the control sample.
detected for the simultaneous treatment 
with the two factors. Th is lack of an addi-
tive effect indicates that in embryonic 
dopamine neurons VEGF-C and GDNF 
aff ect the same population of neurons.
Gene expression levels for GDNF 
and VEGF-C signalling receptors and 
associated genes were measured by quan-
titative RT-PCR from both the embryonic 
cultures as well as from adult mouse SN 
samples. The mRNA from embryonic 
dopamine cultures and adult mouse mid-
brains expressed both Vegfr-1 and -2, 
but Vegfr-3 was virtually not expressed. 
Th e VEGF family co-receptors Nrp1 and 
Nrp2 mRNAs were expressed at relatively 
high levels in both embryonic and adult 
samples. In addition, the gene expres-
sion levels of Vegf-C, Th , Vegfr-1,-2 and 
-3 were measured by qRT-PCR from rat 
brain treated with VEGF-C (20 μg) for 8h. 
Th is treatment resulted in up-regulation 
of all Vegfr levels in SN by 1.5, 2.1 and 
2.0-fold, respectively, for Vegfr-1,-2 and 
-3. A slight up-regulation of 1.6-fold was 
also detected for Vegf-C, whereas the Th  
expression remained unchanged. A simi-
lar result was seen in embryonic midbrain 
cultures treated with VEGF-C (100ng/ml) 
for 48h, where Vegfr-1 was up-regulated 
by 2.1 and Vegfr -3 by 1.7-fold. Vegfr-2 
mRNA levels in this setup remained 
unchanged. VEGF-C binds preferably to 
VEGFR-3, however, binding to VEGFR-2 
has been also demonstrated and is associ-
ated with the angiogenic eff ects of VEGF-
C. VEGFR-3 is highly expressed during 
development, but in adult mice its expres-
sion is restricted to lymphatic endothe-
lium. VEGFR-3 seems to function during 
the formation of new lymphatic vessels, 
as mature lymphatic vessels do not seem 
to depend on VEGFR-3 (Lohela, Bry et 
al. 2009). VEGR-2 is expressed on lym-
phatic and endothelial cells, but also on 
other cells including neurons (Tammela, 
Enholm et al. 2005). Our results indicate 
that VEGF-C can act via up-regulating 
the expression of its receptor in these neu-
ronal systems.
We further decided to study the 
VEGF-C signalling in the nervous system, 
as crosstalk between RET and VEGFR-2 
in a cell line has been described previ-
ously (Tufro, Teichman et al. 2007). Due 
to technical diffi  culties we could not per-
form the RET phosphorylation assay from 
embryonic DA cultures, thus we tested 
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diff erent cell lines (MG87, MN9D, Neuro 
2A-20) for RET phosphorylation. How-
ever, in our hands 100 ng/ml of VEGF-C 
treatment for 10 minutes did not cause an 
increase in RET phosphorylation com-
pared to untreated samples in any of the 
cell lines tested, although 100 ng/ml of 
GDNF induced a robust phosphorylation 
of RET. We then investigated the involve-
ment of MAPK/ERK downstream sig-
nalling pathways in embryonic midbrain 
cultures treated with VEGF-C (100ng/ml) 
for 45 minutes, which resulted in slight 
phosphorylation of ERK as compared to 
the robust eff ect of GDNF treatment. Th is 
result was confirmed in samples from 
adult rat striatum treated with VEGF-
C (20 μg/per rat) for 1h, which induced 
a significant 24% (p=0.024) increase in 
ERK phosphorylation as compared to 
contralateral vehicle injected striatum. 
Further behavioural studies concen-
trated on the in vivo role of VEGF-C in 
a rat model of PD. Th e neuroprotection 
studies measured rotational behaviour 
when pre-treatment with VEGF-C, GDNF 
or a combination of the two factors was 
performed prior to the 6-OHDA lesion. 
A reduction in the ipsilateral rotations 
between the control group and the 30 μg 
VEGF-C treatment group was seen at 2 
weeks (p=0.012) and the reduced rota-
tional behaviour was highly significant 
(p=0.004) at 4 weeks post-treatment. At 
six weeks all groups treated with VEGF-
C showed less rotation, however these 
results were not statistically significant. 
Our results show that VEGF-C can act as 
a neuroprotective molecule for nigral DA 
neurons in vivo. 
Th e TH-positive cells were counted 
in the SN of the rats used in neuroprotec-
tion studies and the combination group 
receiving the simultaneous administration 
of VEGF-C and GDNF showed the most 
eff ective protection of nigral neurons by 
97% as compared to 61% of the control 
group (p=0.004). GDNF treatment alone 
showed a neuroprotective effect of 84% 
(p=0.004) and VEGF-C treatment showed 
an eff ect of 70-73%, which was statistical-
ly not signifi cant (p=0.056). 
To quantify the nerve endings in 
the striatum of rats following 6-OHDA 
lesions optical density of TH-immuno-
reactivity can be measured. The optical 
density was higher in all the growth factor 
treatment groups – 56 to 58% for VEGF-
C (p>0.05), 70% for GDNF (p=0.012) and 
67% for the combination of VEGF-C and 
GDNF (p>0.05), as compared to 38% for 
the control group (IV). 
We further evaluated whether the 
neuroprotective eff ects of VEGF-C could 
be mediated by indirect angiogenic 
effects. Indeed increased angiogenesis 
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Figure 8. VEGF-C induces ERK posphoryla-
tion in embryonic midbrain cultures. Activa-
tion of MEK/ERK pathway is very mild fol-
lowing VEGF-C treatment as seen by Western 
blotting. Treatment of E13 midbrain dopa-
minergic cultures with VEGF-C for 45 min 
resulted in slight phosphorylation of ERK, 
GDNF treatment induced robust phosphory-
lation of ERK.
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in vivo was measured in the striatums of 
6-OHDA- lesioned rats in the VEGF-C 
treatment groups, with 12% (p=0.041) 
more blood vessels in the VEGF-C 20 μg 
treatment group. In addition, the tube for-
mation assay for VEGF-C was performed 
in HUVEC cells, which showed that 
VEGF-C (100ng/ml) could induce tube 
formation at 2h (p=0.001) whereas GDNF 
treatment results did not diff er from the 
control samples.
Further immune markers staining 
for astrogliosis and microgliosis was mea-
sured from adult rat striatum injected 
with 20 μg VEGF-C, 3 days aft er admin-
istration. VEGF-C injection induced a 
robust increase in glial fibrillary acidic 
protein (GFAP) staining  (p=0.003), 
however, no signifi cant change in GFAP 
staining was seen in selected striatums 
from the neuroprotection experiments in 
6-OHDA treated animals in comparison 
between the vehicle, VEGF-C and GDNF 
treatment, although prominent astro-
gliosis was seen around the needle in all 
treatment groups. Also the staining for 
microglial marker Iba-1 was measured 
in VEGF-C treated rats and prominent 
microglial activation was observed follow-
ing 20 μg VEGF-C treatment (p=0.001). 
BBB disruption was studied from the 
VEGF-C injected rat brains. There was 
clearly less EBA-immunoreactive blood 
vessel staining around the needle cavity in 
VEGF-C treated striatums as compared to 
the control side (p=0.001), which is indic-
ative of BBB disruption following VEGF-
C treatment. 
The lymphangiogenic properties of 
VEGF-C are well established, however 
this study was the first time the neuro-
trophic eff ects of VEGF-C in the dopami-
nergic system have been evaluated. 
4.7 GDNF eﬀ ects in the vascular 
system
Regarding the evaluation of vascular 
events related to GDNF signalling, we 
initially hypothesized that GDNF by up-
regulating VEGF-C might aff ect the vas-
culo-lymphatic system and regulate the 
innervation of vasculature. We performed 
analysis of GDNF KO and wt animal vas-
cular system on embryonic day 19 just 
before GDNF-defi cient mice die. Initially 
paraffin sections of embryos were pre-
pared and stained with a marker specifi c 
for the lymphatic vessels – Lyve, which 
specifi cally stains the lymphatic endothe-
lial cells. We found 50% less lymphatic 
vessels in skin tissue of GDNF KO ani-
mals as compared to wt mice (n=4) (Plan-
ken et al. unpublished data). We further 
decided to study the branched lymphatic 
structures on whole-mount skin prepara-
tions of E19 GDNF and RET KO and wt 
animals. However, using this methodol-
ogy we could not confi rm the eff ect of a 
decrease in VEGFR-3 staining - another 
specifi c marker of lymphatic vessels. Nei-
ther did we see any change in PECAM 
staining, which is a panendothelial anti-
body staining the blood vessel endothe-
lia (Planken et al. unpublished data). As 
the whole-mount preparations are more 
convenient for the visualization of three 
dimensional ramifi ed network structures 
than two-dimensional sectioned tissue, 
we concluded that GDNF does not infl u-
ence the development of lymphatic- and 
blood vessels during embryonic develop-
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ment and these structures appear normal 
in GDNF KO animals.
4.8 Crosstalk of neuronal and 
vascular systems
This study on the mechanisms of pos-
sible crosstalk between the neuronal and 
vascular systems was initiated by the 
gene expression fi ndings from the Neu-
ro2A-20 study, demonstrating that GDNF 
up-regulates the main lymphatic growth 
factor VEGF-C.  As the data regarding the 
investigation of vascular eff ects of GDNF 
did not provide any evidence of GDNF-
mediated changes in blood or lymphatic 
vessels, we concentrated on the eff ects of 
VEGF-C in the nervous system. Th ere is 
ample data on the neurotrophic effects 
of VEGF-A in various neuronal systems, 
however when we initiated our study, 
no paper studying the eff ects of VEGF-
C on the nervous system had been pub-
lished. Th e fi rst paper studying the eff ect 
of VEGF-C on nervous system was pub-
lished by Le Bras et al., demonstrating 
that VEGF-C acts as a trophic factor for 
neural progenitors in the vertebrate brain 
(Le Bras, Barallobre et al. 2006). We have 
further collaborated with Dr. Kirsi Sainio 
and Prof. Kari Alitalo groups investigat-
ing the eff ects of VEGF-C on the sympa-
thetic nervous system, demonstrating that 
VEGF-C promotes the proliferation and 
survival of early sympathetic progenitors 
(Piltti doctoral dissertation 2009; Piltti, 
Planken et al. submitted). In this study 
we showed that the eff ects of VEGF-C on 
the induction of sympathetic progenitor 
cell (SPC) proliferation and survival are 
comparable to the eff ects of GDNF and 
ARTN. In addition, VEGF-C KO mice 
were shown to exhibit decreased size 
of sympathetic ganglia. In this system 
VEGF-C also activated ERK downstream 
signalling pathway, independent of VEG-
FR-3 and -2, as these receptors were not 
expressed in sympathetic progenitors. 
Interestingly we also observed that the 
SPCs isolated and cultured from RET KO 
and Hz animals failed to increase their 
proliferation in the presence of VEGF-
C unlike the control samples. However, 
VEGF-C was unable to induce direct RET 
phosphorylation (Piltti, Planken et al. 
submitted).   
Thus the results from these stud-
ies clearly demonstrate the neurotrophic 
properties of a well characterized lym-
phangiogenic factor -VEGF-C on diff er-
ent neuronal systems including the neu-
ral progenitors, developing sympathetic 
neurons as well as the dopaminergic 
neurons in embryonic and adult stage. In 
our study on the dopaminergic eff ects of 
VEGF-C we described VEGF-C to be a 
neurotrophic factor for embryonic dopa-
minergic neurons in vitro, as well as to act 
as the neurotrophic and neuroprotective 
protein in the adult rat neurotoxin mod-
el of PD. The exact signalling pathways 
which mediate the neurotrophic eff ects of 
VEGF-C in the neuronal systems are not 
clear. In embryonic dopamine cultures we 
observed the expression of Vegfr-1 and -2, 
but no expression of Vegfr-3, neither did 
the midbrain lysates isolated from adult 
mice express detectable levels of Vegfr-3. 
Following treatment of rat striatums with 
VEGF-C for 8h we could see up-regula-
tion of all Vegfrs by up to 2 fold, which 
was also visualized in VEGF-C treated 
samples from embryonic midbrain cul-
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tures where we could see up to 2-fold up-
regulation of the Vegfr-1 and -3 mRNA, 
whereas Vegfr-2 remained unchanged 
in this setup. Also the VEGF family co-
receptors neuropilins showed signifi cant 
expression. However, both the embryonic 
DA cultures, as well as brain lysates, con-
tain numerous other cells, thus the exact 
expression patterns in the dopamine cells 
cannot be confi rmed. Our results on SPCs 
did not show any expression of Vegfrs-2 
and -3, however up-regulation following 
VEGF-C treatment was not tested (Piltti 
submitted). Very low expression of Vegf 
receptors in dopaminergic neurons was 
also seen in VEGF-A dopamine study 
(Yasuhara, Shingo et al. 2004). Krum et al. 
found no expression of Vegfr-2 in normal 
brain, but noticed induction of expres-
sion of Vegfr-1 and -2 following infusion 
of vehicle or VEGF-A (Krum, Mani et al. 
2002). Both our studies  demonstrated 
downstream ERK/MAPK pathway activa-
tion, but failed to show any direct cross-
talk on the level of RET phosphorylation 
by VEGF-C, as has been previously dem-
onstrated for VEGF-A (Tufro, Teichman 
et al. 2007). Th us the results from SPCs 
proliferation assays in RET KO and Hz 
animals (where VEGF treatment, unlike 
in the control samples, failed to induce an 
increase in proliferation) (Piltti, Planken 
et al. submitted) needs further investiga-
tion.
Th e eff ects of VEGF-C in the nervous 
system might also be mediated by infl u-
ences from other systems in the brain, 
such as the immune or vascular system. 
We found increased number of blood 
vessels in VEGF-C treated and 6-OHDA 
injured rat striatums. The increase in 
blood circulation might prove to be ben-
efi cial to neuronal survival and recovery 
as has been postulated for VEGF-A-treat-
ed 6-OHDA-lesioned animals (Yasuhara, 
Shingo et al. 2004; Yasuhara, Shingo et al. 
2005; Yasuhara, Shingo et al. 2005). How-
ever, negative eff ects of possible extrava-
sation and vessel leakage must be kept 
in mind for possible therapeutic appli-
cations. Another observation evoking 
concern, regarding possible therapeutic 
potential of VEGF-C, is the eff ect of BBB 
disruption which was demonstrated to be 
present in VEGF-C injected rat brain. In 
addition the VEGF-C treatment triggered 
microglial activation around the injection 
area. Th e mechanistic eff ects of microg-
lial activation in this setting remain to be 
investigated, as both detrimental and ben-
efi cial eff ects have been described for this 
process.
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Concluding remarks
5. CONCLUDING REMARKS
Th e current study has evaluated the role of GDNF in the midbrain dopaminergic system 
and investigated the crosstalk with other growth factors. Th is is the fi rst study demon-
strating the role of VEGF-C as a neurotrophic factor for midbrain dopaminergic neurons 
in the culture and in vivo. Some of the specifi c conclusions from the results are the fol-
lowing:
1. GDNF regulates gene expression in diff erent neuronal systems, and up-regulates 
genes of the immune and vascular system. In Neuro 2A cells GDNF strongly up-
regulates VEGF-C, a growth factor for lymphatic vessels
2. Heterozygous GDNF knockout mice have increased intracellular dopamine con-
centrations and FosB/ΔfosB levels in the midbrain without signifi cant behavioral 
changes.
3. GDNF receptor RET MEN2B mutation in knock-in mice leads to increased extra-
cellular dopamine and its metabolite levels, increased number of nigrostriatal dopa-
mine neurons and dopamine synthesis. Th is demonstrates that RET signaling con-
trols the number of nigral dopamine neurons and regulates dopamine metabolism 
in the striatum.
4. An enhanced computer assisted micro-island method for culturing embryonic mid-
brain DA neurons was developed. Th is method can be utilized for the analysis of 
dopamine neuron survival from limited amounts of neuronal material, for studying 
the additive eff ects of growth factors and for drug screening purposes.
5. VEGF-C promotes neuronal survival of midbrain DA neurons in vitro and protects 
nigrostriatal dopamine neurons in rat 6-OHDA model of Parkinson’s disease. 
6. VEGF-C increases the number of blood vessels in the midbrain of 6-OHDA-lesioned 
rats, but surprisingly also enhances astrogliosis and causes BBB leakage.
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